

Annual Report & Accounts 2016 - 2017



**EAST INDIA PHARMACEUTICAL
WORKS LIMITED**

Contents

2	Board of Directors
3	A Decade at a Glance
4	Directors' Report
23	Independent Auditors' Report
28	Balance Sheet
29	Statement of Profit & Loss
30	Cash Flow Statement
31	Notes
44	Consolidated Financial Statements alongwith Independent Auditors' Report
65	EAST INDIA Organisation
67	Names & Addresses of C & F Agents

Board of Directors

Dr. Ranabir Mukherji
Mr. Dilip Samadar
Mr. Probir Roy
Prof. (Dr.) Suman Kumar Mukerjee
Prof. (Dr.) Himadri Sengupta
Mr. Sukamal Chandra Basu

Mr. Chiraranjan Addy
Dr. Abhijit Banerjee
Dr. Tapas Raychaudhury
Mr. Amit Kumar Sen (Managing Director)
Mr. Debarshi Duttagupta (Managing Director)

Secretary & Chief Compliance Officer

Mr. Nirjhar Mukhopadhyay

Chief Financial Officer

Mr. Subrata Ray

Statutory Auditors

M/s APS Associates
Chartered Accountants
3-C, Madan Street, 1st Floor
Kolkata 700 072

Cost Auditors

M/s DGM & Associates
Cost Accountants
64, B. B. Ganguly Street, (2nd. Floor),
Kolkata 700 012

Registrar and Share Transfer Agent

C B Management Services (P) Ltd.
P-22, Bondel Road, Kolkata - 700 019
Phone: (033) 4011 6700/2280 6692
Fax: 91-33- 2287 0263
CIN: U74140WB1994PTC062959
E-Mail: rta@cbmsl.com
Website: www.cbmsl.com

Principal Banker

United Bank of India
Hazra Road Branch
53, S. P. Mukherjee Road, Kolkata 700 026

Bankers

Andhra Bank, AXIS Bank Ltd., Bank of Baroda, Bank of India, Central Bank of India, HDFC Bank Ltd., HSBC Limited, Indian Bank, Indian Overseas Bank, Kotak Mahindra Bank, Punjab National Bank, State Bank of India, State Bank of Travancore, The Kapol Co-operative Bank Ltd. & Union Bank of India.

Registered Office

6, Nandalal Bose Sarani, Kolkata 700 071
CIN : U24231WB1936PLC008598
Website : www.eastindiapharma.org

A Decade At A Glance

	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Fixed Assets	1876.04	1605.25	1088.12	1103.69	1260.99	1402.34	1367.92	1401.32	1518.51	1514.75
Current Assets, Loans & Advances	10510.83	10258.31	9599.97	9176.10	8008.28	7220.88	6885.54	6191.97	5389.37	5025.11
Share Capital	667.45	667.45	667.45	667.45	667.45	667.45*	444.97	444.97	444.97	444.97
Reserves & Surplus	3585.16	3395.23	3113.55	2980.59	2751.12	2907.45	2857.42	2540.97	2329.62	2142.00
Loans	3303.70	2765.10	2223.47	2247.17	2449.85	2211.66	2086.67	2020.61	1865.32	1668.50
Current Liabilities & Provisions	5160.87	5351.76	4992.93	4684.44	3680.55	3077.77	3087.41	2771.09	2409.68	2385.36
Sales	15975.19	15763.80	14650.61	13561.78	12604.61	13375.27	12317.40	11523.93	10621.26	10312.12
Cost of Materials	4474.06	4574.03	4553.44	4204.59	4268.94	4051.96	3722.51	3890.29	3722.08	3166.44
Staff Expenses	5023.96	4626.10	4281.89	3774.07	3615.90	3608.24	3347.13	3087.13	2794.49	2428.82
Contribution to Exchequer	2094.26	2074.26	2038.06	1737.49	1455.00	1591.85	1378.26	1065.60	1033.49	1634.58
Finance Cost	485.40	499.21	401.05	421.69	403.05	324.91	252.92	226.21	223.77	168.67
Profit/(Loss) Before Tax	255.47	489.90	411.30	321.87	(194.91)	566.88	657.04	589.33	473.04	382.94
Profit/(Loss) After Tax	189.93	362.02	172.93	307.04	(156.32)	388.87	472.11	351.44	317.77	254.80
Profit/(Loss) Retained	189.93	281.68	92.59	229.46	(156.32)	272.51	316.45	211.35	187.62	137.66
Dividend on Ordinary Shares	5%+	10%	10%	10%	NIL	15%	30%	27%	25%	22.5%

All figures are in lakhs ₹

+ Subject to the approval by the Shareholders in the AGM

* Bonus Shares issued 1:2 capitalising from General Reserve.

Directors' Report

Dear Members

Your Directors have pleasure in presenting the 80th. Annual Report on the business and operations of the Company together with Audited Financial Statements for the year ended March 31, 2017.

Financial Results:

The financial results for the year are as under:

<u>Particulars</u>	<u>2016-17(₹)</u>	<u>2015-16(₹)</u>
Profit Before Depreciation, Interest & Tax (PBDIT)	88818909	113270444
Interest / Finance Charges	48539902	49921240
Profit Before Depreciation and Tax (PBDT)	40279007	63349204
Depreciation / Amortization	14732057	14358909
Profit Before Tax (PBT)	25546950	48990295
Taxation Charge		
- Current Tax	4600000	13000000
Deferred Tax Charge / (Written Back)	(1433529)	(667614)
- Tax adjustment of earlier years	3387777	456178
Profit After Tax (PAT)	18992702	36201731
Balance available for appropriation	18992702	36201731
Appropriations		
Proposed Dividend	NIL	6674518
Corporate Dividend Tax	NIL	1359001
Transfer to General Reserve	18992702	28168212
Surplus carried to Balance Sheet		
Earnings per Ordinary share		
- Basic	2.85	5.42
- Diluted	2.85	5.42
Dividend per Ordinary Share	Nil	1.00

Dividend

Your Company has a consistent track record of dividend payment. Your Directors are pleased to recommend a dividend of ₹ 0.50/- (5%) per share of ₹ 10/- each on Equity Share Capital of the Company for the financial year ended March 31, 2017 for your approval at the ensuing Annual General Meeting. The dividend if approved, shall be payable to the members holding shares as on record date i.e. 1st. September, 2017.

The year in retrospect - Management Analysis

Like last year NPPA once again reduced prices of our 12 Schedule Drugs, in spite of rising cost on every front.

The biggest impact last year was the employees' cost. It has grown up by approximately 4 crores during the year resulting in cash crunch as well as the profit margin of the company. The sale also marginally increased from ₹ 157.64 crores to ₹ 159.75 crores thus reducing the profit to ₹ 2.56 crores from ₹ 4.90 crores. The management is trying its level best to tackle the situation on an emergency basis but due to introduction of the GST it is finding it difficult to handle the same.

I think most of you are aware that most the dealers have not registered themselves with the GST. The same is particularly true for West Bengal since the tax was paid on the single point basis. Most of our dealers have not taken

Directors' Report

care to get them registered. As a result they are finding it extremely difficult to get themselves registered under the new GST regime. In spite of repeated warning by the Central Govt. to get them registered by 30th. June they have failed to do so and as a result most of them have not been able to start the business for the current year. This will make a negative impact for the company in the current year.

The Pharmaceutical industry, last year, has grown 1011 billion and it is forecast to growth rate of 11-14 % over the next 4 years. It continues to be highly fragmented and competitive market with the large number of players in the therapeutic regiment. We sincerely hope that we will be able to catch a part of the growth during the next 4 years.

Transfer of Unclaimed Dividend/Shares to Investor Education and Protection Fund

Pursuant to Section 124 of the Companies Act, 2013 amounts lying unclaimed or unpaid in the unpaid dividend accounts of the Company, is required to be transferred to the Investor Education and Protection Fund (IEPF) of the Central Government after such amount has been remained unclaimed or unpaid for a period of seven years from the date of transfer to the unpaid dividend account.

During the year, the Company transferred an amount of ₹ 16, 90, 977.50/- to the IEPF being the unclaimed dividend for the financial year ended 31.03.2009.

The Ministry of Corporate Affairs, Government of India has notified section 124(6) of the Companies Act, 2013 along with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 with effect from 7th. September, 2016. In terms of the provisions of the aforesaid, shares of the company for which dividend are lying unpaid or unclaimed for a period of consecutive seven years, from the date of transfer to unpaid dividend account, shall be transferred to DEMAT Account of Investor Education and Protection Fund Authority after serving individual notices to concerned shareholders at there registered addresses and publishing notice in newspapers. The Company in accordance with the law, has given notice in newspaper and had served individual notices to the concerned shareholders whose shares were liable to be transferred to DEMAT Accounts of IEPF. However, the Ministry of Corporate Affairs, is yet to finalize the modalities of transferring the shares to IEPF DEMAT Accounts. As soon as the Ministry finalize and notifies the procedure of transferring the shares, that would be complied with.

Subsidiary Companies and Consolidated Financial Statements

As on 31st March, 2017, the Company has one wholly owned subsidiary namely "Qasar Healthcare Private Ltd.".

The Consolidated Financial Statement of the Company and its subsidiary, prepared in accordance with relevant Accounting Standards specified in the Companies Act, 2013 read with the Rules made there under, forms part of the Annual Report. The necessary information as required to be given in terms of the first proviso of sub-section 3 of Section 129 of the Companies Act, 2013 is given in this Annual Report.

In terms of -

- (i) Clause (a) of fourth proviso to sub-section (1) of Section 136 of the Companies Act, 2013, a copy of the Balance Sheet, Statement of Profit and Loss and other documents of its subsidiary company shall be placed on the website of the Company, viz. www.eastindiapharma.org.
- (ii) Clause (b) of fourth proviso to sub-section (1) of Section 136 of the Companies Act, 2013, the said documents/details shall be made available, upon request, to any member of the Company.

Accreditation

The Company continues to enjoy ISO 9001-2008 certification by DET NORSKE VERITAS (DNV) and GMP - Schedule M (2001) compliance certificate from Directorate of Drugs Control, W.B.

Transfer to General Reserve

An amount of ₹ 1,89,92,702/- is proposed to be transferred to the general reserve.

Public Deposits

During the year under review the Company did not accept any deposits from public within the ambit of Section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014.

Directors' Report

Material Changes and Commitments Affecting Financial Position Between end of the Financial Year and Date of Report

There have been no material changes and commitments which have occurred subsequent to the close of the financial year of the company to which the financial statements relates and the date of the report.

Changes in Directors and Key Managerial Personnel

There has not been any change during the year.

Pursuant to Section 152 of the Companies Act, 2013 and in terms of the Articles of Association of the Company, Prof. (Dr.) Suman K Mukerjee (DIN 01262841) & Dr. Tapas Raychaudhury (DIN 00711365), Directors of the Company, will retire by rotation at the ensuing Annual General Meeting and being eligible, offer themselves for re-appointment. Your Board has recommended their re-appointment. Brief profiles of Prof (Dr.) Suman K Mukerjee and Dr. Tapas Raychaudhury are mentioned in Annexure I of this report.

During the year under review, pursuant to the provisions of Section 2(51) and Section 203 of the Companies Act, 2013 read with the rules made there under, the following existing officials of the Company were designated / classified as whole time Key Managerial Personnel of the Company -

1. Mr. Amit Kumar Sen & Mr. Debarshi Duttagupta both Managing Director;
2. Mr. Nirjhar Mukhopadhyay, Secretary & Chief Compliance Officer; and
3. Mr. Subrata Ray, Chief Financial Officer.

Number of Meetings of the Board of Directors

The Board of Directors of the Company met 5 (Five) times during the year 2016-17 i.e. on 24th. June, 2016, 11th. August, 2016, 23rd September, 2016, 30th December, 2016 & 18th March, 2017.

The gap between two consecutive meetings did not exceed one hundred twenty days.

Sl. No.	NAME	No. of Board Meetings attended during 2016-17		Whether attended last AGM held on 16.09.2016
		Held	Attended	
1.	Dr. Ranabir Mukherji	05	04	Yes
2.	Mr. Probir Roy	05	05	Yes
3.	Mr. Sukamal Chandra Basu	05	05	Yes
4.	Mr. Dilip Samadar	05	03	Yes
5.	Dr. Himadri Sengupta	05	02	Yes
6.	Prof. Suman Kumar Mukerjee	05	05	Yes
7.	Mr. Chiraranjan Addy	05	05	Yes
8.	Dr. Abhijit Banerjee	05	05	Yes
9.	Dr. Tapas Raychaudhury	05	03	Yes
10.	Mr. Amit Kumar Sen	05	05	Yes
11.	Mr. Debarshi Duttagupta	05	05	Yes

Audit Committee

The composition, terms of reference etc. of the Audit Committee is provided below :

Members :

- | | |
|--|-----------------------|
| <ol style="list-style-type: none"> (a) Mr. Probir Roy (b) Mr. Sukamal Chandra Basu (c) Mr. Dilip Samadar (d) Mr. Amit Kr. Sen (e) Mr. Debarshi Duttagupta | Independent Directors |
|--|-----------------------|

Directors' Report

The Audit Committee is constituted in accordance with Section 177 of the Companies Act, 2013.

The Audit Committee comprises of three Independent, Non-Executive Directors namely Mr. Probir Roy, Mr. Sukamal Chandra Basu and Mr. Dilip Samadar. Mr. Amit Kumar Sen, Managing Director and Mr. Debarshi Dutttagupta, Managing Director are also members of the Audit Committee. The Chief Financial Officer, Chief Accountant, Internal Auditor, Statutory Auditor and Cost Auditor are permanent invitees to the meetings of the Audit Committee. The Secretary and Chief Compliance Officer acts as the Secretary to the Audit Committee. The Committee reviews Financial Statements, Internal Control Mechanism, Vigil Mechanism and the Internal Audit Report and such other matters as may be required as per the provisions of the Companies Act, 2013 and Terms of Reference of the Audit Committee.

The Audit Committee has met on 11th August, 2016 during the financial year 2016-17.

All the Members except Mr. Dilip Samadar attended the meeting. Mr. Dilip Samadar was given leave of absence.

There have been no instances of non-acceptance of any recommendations of the Audit Committee by the Board during the financial year under review.

Independent Directors Meetings

Members :

- (a) Mr. Probir Roy
- (b) Mr. Sukamal Chandra Basu
- (c) Mr. Dilip Samadar

The Independent Directors met on 24th August, 2016 to discuss the matters as envisaged in Schedule IV to the Companies Act, 2013.

All the Directors except Mr. Sukamal Chandra Basu were present. Mr. Sukamal Chandra Basu was given leave of absence.

Vigil Mechanism / Whistle Blower Policy

The Company has established a Vigil Mechanism / Whistle-blower mechanism under the Vigil Mechanism Policy to provide a formal mechanism to the directors, employee and stakeholders to report genuine concerns about unethical behavior, actual and suspected fraud or violation of the Company's policies. The Vigil Mechanism Policy has been uploaded on the website of the Company at www.eastindiapharma.org.

The Audit Committee of the Company oversees the Vigil Mechanism.

Declaration of Independence

In terms of provisions of the Section 149(7) of the Companies Act, 2013, all the Independent Directors of the Company have furnished a declaration to the Compliance Officer of the Company at the meeting of the Board of Directors held on 24th June, 2016 stating that they fulfill the criteria of Independence as prescribed under section 149(6) of the Companies Act, 2013 and are not being disqualified to act as an Independent Director.

Directors' Responsibility Statement

As required by Section 134 (5) of the Companies Act, 2013, based on the information and representations received from the operating management, your Directors confirms that:

- (a) in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- (b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit & loss of the Company for that period;
- (c) the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) the Directors have prepared the annual accounts on a 'going concern' basis;

Directors' Report

- (e) the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively;
- (f) the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Board Evaluation

The Performance evaluation of the Board, its committee and individual Directors was conducted and the same was based on framework of evaluation for all the Directors on the Board as a whole, its committees and self- evaluation.

The Chairperson of the Nomination and Remuneration Committee (NRC) held separate discussions with each of the Directors of the Company and obtained their feedback on overall Board effectiveness as well as on each of the other Directors.

Based on the framework of Board Evaluation, the performance of every Director was evaluated by the NRC. Some of the key criteria of the framework of performance evaluation, as laid down by the NRC were as follows-

Performance evaluation of Directors :

- n Contribution at Board/ Committee meetings
- n Guidance/ Support to Management outside Board / Committee Meetings

Performance evaluation of Board and Committees:

- n Board structure and composition
- n Degree of fulfillment of key responsibilities
- n Establishment and delineation of responsibilities to Committees
- n Effectiveness of Board processes, Information and Functioning
- n Board Culture and Dynamics
- n Quality of relationship between the Board and Management
- n Efficacy of communication with External Stakeholders
- n Committees- strengths and areas of improvement

Nomination and Remuneration Committee & Remuneration Policy

The composition, key objectives etc. of the Nomination and Remuneration Committee is given below:

Members:

- (a) Mr. Probir Roy
- (b) Mr. Sukamal Chandra Basu
- (c) Prof. (Dr.) Suman K Mukerjee

The Committee met on 24th August, 2016. The meeting was attended by all the members.

The Committee has formulated a Nomination and Remuneration Policy which has been provided in Annexure II to this Report and the same has been uploaded on the website of the Company at www.eastindiapharma.org.

Stakeholders' Relationship Committee

Members:

- (a) Mr. Chiraranjan Addy
- (b) Dr. Himadri Sengupta
- (c) Dr. Abhijit Banerjee

The Committee met 4 (Four) times during the financial year 2016-17, on 24.05.2016, 09.09.2016, 16.12.2016 and 18.03.2017.

The Committee is empowered to consider and approve the physical transfer/transmission/transposition of shares, issue of new/duplicate share certificates. The Committee also specifically looks into the Redressal of shareholders' and investors' complaints/grievances pertaining to transfer of shares, non-receipt of dividend warrants, etc.

Directors' Report

During the financial year 2016-17 the Committee has received no complaints from any shareholder or investor.

Disclosure under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

In accordance with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made there under, the Company formulated an internal Policy on Sexual Harassment at Workplace (Prevention, Prohibition and Redressal) during the year under review.

The policy aims at educating employees on conduct that constitutes sexual harassment, ways and means to prevent occurrence of any such incident, and the mechanism for dealing with such incident in the unlikely event of its occurrence. A five member Internal Complaints Committee (ICC) has been constituted in accordance with the Act.

The ICC is responsible for Redressal of complaints related to sexual harassment of women at the workplace in accordance with procedures, regulations and guidelines provided in the Policy.

During the year under review there were no complaints referred to the ICC.

Corporate Social Responsibility

The Company was not required to constitute a Corporate Social Responsibility Committee during the year under review.

Related Party Transactions

All related party transactions those were entered during the financial year were in the ordinary course of business and on an arm's length basis. There were no materially significant related party transactions entered into by the Company with promoter, directors, key managerial personnel or other persons which may have a potential conflict with the interest of the Company. Since all the related party transaction entered into by the Company were in the ordinary course of business and were on arm's length basis and there were no material related party transactions during the year, Form AOC-2 is not applicable to the Company.

Auditors And Auditors Report

The Auditors, M/s, APS Associates, Chartered Accountants (Firm Registration No. 306015E) were re-appointed as the Statutory Auditor of the Company under Section 139 of the Companies Act, 2013 to hold office for a period of five years up to the conclusion of the 82nd Annual General Meeting to be held in the year 2019. Their appointment is eligible for ratification for the financial year 2016-17. Your Board recommends ratification of their appointment as the Statutory Auditors at the ensuing Annual General Meeting for a period up to the conclusion of the 82nd Annual General Meeting of the Company.

Auditors' Report

The notes on account referred to in the Auditors' Report are self-explanatory and therefore, do not call for any further explanations or comments.

There are no qualifications, reservations or adverse remarks or disclaimer made in the Auditors' Report, which requires any clarification or explanation.

The Statutory Auditors have not reported any incidence of fraud to the Audit Committee of the Company during the year under review.

Cost Auditor

Pursuant to section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with Companies (Audit and Auditors) Rules, 2014, the Board of Directors of your Company have appointed M/s DGM & Associates, Cost Accountants as the Cost Auditor for FY 2017-2018 for conducting the audit of cost records of the Company on the recommendations made by the Audit Committee. The remuneration proposed to be paid to the cost auditor is subject to ratification by the members at ensuing Annual General Meeting and a resolution regarding ratification of remuneration payable to M/s DGM & Associates, Cost Accountants, forms part of the Notice convening the 80th Annual General Meeting of the Company.

Internal Control System

The Company has adequate internal control system commensurate with its size and scale of operations. The Internal Auditor review that all the transactions of the Company are in line with the compliance of laws, policies and procedures and have been correctly recorded and reported. The internal Audit is conducted on regular basis and the report sare submitted to the Audit Committee at their meetings.

Directors' Report

Human Resources

As on 31st March, 2017, the Company had 1219 employees including 257 managerial personnel.

The Company has excellent combination of experienced and talented Technical Managers. The Company also undertakes on regular basis various training programmes to keep its employees updated on new technical developments and information, which directly results in optimum capacity utilization and cost effectiveness.

The Company's relation with its employees continues to be cordial. The Company always reciprocates commitments to its employees in order to motivate them to perform the best.

Statutory Compliances

All declarations and compliances with respect to the applicable statutes, enactments and guidelines are submitted at every meeting of the Board of Directors of the Company. The Company Secretary who is also the Compliance Officer gives a declaration of compliance to the Board with respect to the applicable provisions of Companies Act, 2013.

Adoption of New Articles of Association

The Ministry of Corporate Affairs, Government of India has notified most of the sections of the Companies Act, 2013 which have replaced various provisions of the Companies Act, 1956. In view of the changes in Companies Act, it is felt necessary to bring the Articles of Association of the Company in line with the provisions of Companies Act, 2013. Accordingly, the Board has proposed for adoption of a new set of Articles of Association. A Special Resolution to this effect forms part of the Notice convening the 80th Annual General Meeting of the Company.

Particulars of Loans, Guarantees or Investments

During the period under review, the Company has not given any loan, guarantee or made any investment in terms of provisions of Section 186 of the Companies Act, 2013.

Particulars Of Employees

There are no employees whose particulars are required to be published under Section 197 of the Companies Act, 2013 and rules made there under.

Energy Conservation, Technology Absorption and Foreign Exchange Earnings and Outgo

The particulars relating to energy conservation, technology absorption, foreign exchange earnings and outgo, required to be disclosed by Section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 are provided in the Annexure-III to this Report.

Risk Management

A robust and integrated enterprise risk management framework is in existence under which the common prevailing risks in the Company are identified, the risks so identified are reviewed on periodic basis by the Risk Management Committee and the management's actions to mitigate the risk exposure in a timely manner are assessed. The Company has taken adequate measures to mitigate various risks encountered by the Company.

A risk management policy under the above said enterprise risk management framework as approved by the Board has been adopted by the Company and being reviewed on yearly basis.

Extract of Annual Return

The extract of the Annual Return in Form MGT-9, as required under Section 92(3) of the Companies Act, 2013 read with Rule 12(1) of the Companies (Management and Administration) Rules, 2014 is attached as "Annexure IV" to this Report.

Going Concern Status

No significant and material orders have been passed by the Regulators or Courts or Tribunals impacting the going concern status of the Company and its operations in the future.

Appreciation and Acknowledgment

Your Directors would like to express their appreciation for the assistance and co-operation received from the Government authorities, Banks, customers, business associates medical fraternity and members during the year

Directors' Report

under review. Your Directors also wish to place on record their deep sense of appreciation for the committed services by the executives, staff and workers of the Company.

Place: Kolkata
Date: August 7, 2017

for and on behalf of the Board of Directors
Sd/- Dr. Ranabir Mukherji
Chairman

ANNEXURE - I TO THE DIRECTORS

Brief Profile of Directors seeking re-appointment at the Annual General Meeting

Prof. (Dr.) Suman K Mukerjee

Date of Birth: 2nd August, 1949

Qualification: M.A., Ph. D

Resume:

- i) Fellow, All India Management Association
- ii) Environmental Fellow, USAEP (under USAID)
- iii) Member of Indo British Scholars' Association
- iv) He is a faculty of Delhi University Colleges, IIT (Delhi), St. Xavier's College, Calcutta, Professor to XLRI, Jamshedpur and IISWBM, Calcutta University.
- v) Visiting Professor of Economics and Management, Sellinger School of Business and Management, Loyola College, Baltimore, USA 1994, 1995. Director of J. D. Birla Institute, (Affiliated to Jadavpur University), Birla School of Management and all Institutions under Sukriti Education Society.
- vi) Presently, he is Director General, The Bhowanipur Education Society College, Kolkata, affiliated with Calcutta University.
- vii) Resource person to UGC's Open University Programme for National Telecasts presented 18 programmes on Economic Development and Planning. Consultant and Editor of Perspective 2000-2003 (a page dedicated to Management, sponsored by IOL), Initially to Business Standard and later Hindustan Times, Calcutta.
- viii) British Council sponsored 'visitor' to British Universities for talks and seminars 1990 and 1995. USAEP Asian Delegate to the World Bank Conference on Sustainable development, Washington, 1994. International Observer at Mr. Bill Clinton's White House conference on Small Business, 1995. Presented papers in national & international conference in Delhi, USA, UK, Australia.
- ix) National Director (Consulting) Ernst & Young, India, Subject Expert to World Bank, Buxa Tiger Project, Consultant to NCAER, Govt. of India, Ministry of Finance Project "Problems of Economic Reforms in India". Industrial Environment Coordinator, to Calcutta Environment Management and Strategy Action Plan (DFID) Project, Govt. of WB. Advisor and Consultant to many corporates (NCJM, Rohtas Inds., ITC, INDAL, etc.) on Management and Policy matters.
- x) Member, State Advisory Council, Govt. of West Bengal.
- xi) Awarded 'Mother Teresa International Award' for excellence in education in 2014.

Dr. Tapas Raychaudhury

Date of Birth: 16th December, 1949

Qualification: M.B.B.S.(Cal), F.R.C.S. (Eng), F.R.C.S. (Edin)

Resume:

- i) Chief Cardiac Surgeon, Anandolok Hospital, Kolkata.
- ii) Fortis Hospital, Kolkata as Senior Consultant Cardiac Surgeon.
- iii) Immediate Past President of Association of Thoracic and Cardio vascular Surgeons of West Bengal.
- iv) He is the Life member of 'Past National Executive Committee', Cardiological Society of India and member of Indian Association of Cardiovascular and Thoracic Surgeons.

Other Achievements: Research Experience -Total no. of Scientific Papers 66 (International 14, National 52)

Directors' Report

ANNEXURE - II TO THE DIRECTORS' REPORT

Nomination and Remuneration Policy

The objectives of this Policy include the following:

- n To lay down criteria for identifying persons who are qualified to become Directors;
- n To formulate criteria for determining qualification, positive attributes and independence of a Director;
- n To determine the composition and level of remuneration, including reward linked with the performance, which is reasonable and sufficient to attract, retain and motivate Directors and KMP, to work towards the long term growth and success of the Company;
- n To frame guidelines on the diversity of the Board;

Definitions :

Unless the context requires otherwise, the following terms shall have the following meanings: "Director" means a Director of the Company.

"Key Managerial Personnel" or "KMP" means -

- (i) the Chief Executive Officer or the Managing Director;
- (ii) the Whole-time Director;
- (iii) the Chief Financial Officer;
- (iv) the Company Secretary; and
- (v) such other officer as may be prescribed under the applicable law.

Criteria for identifying persons who are qualified to be appointed as a Director of the Company:

Section 164 of the Companies Act, 2013 ("Act") provides for the disqualifications for appointment of any person to become Director of any company. Any person who in the opinion of the Board of Directors ("Board") is not disqualified to become a director, and in the opinion of the Board, possesses the ability, integrity and relevant expertise and experience, can be appointed as Director of the Company.

Independent Directors

For appointment of any person as an Independent Director he / she should possess qualifications as mentioned in Section 149 of the Companies Act, 2013 along with the Rules made thereunder.

Appointment criteria and qualifications

The Nomination & Remuneration Committee ("Committee") shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director (including Independent Directors), or KMP and recommend to the Board his / her appointment.

Such person should possess adequate qualification, expertise and experience for the position he/she is considered for appointment. The Committee has discretion to decide whether qualification, expertise and experience possessed by a person is sufficient/satisfactory for the concerned position.

Evaluation

The Committee shall carry out evaluation of performance of every Director or KMP at regular interval and at least on a yearly basis.

Evaluation of Directors

In terms of Section 149 of the Act read with Schedule IV of the said Act the Independent Directors shall at its separate meeting review the performance of non-independent Directors based on the parameters that are considered relevant by the Independent Directors.

The Board as a whole shall evaluate the performance of Independent Directors. During such evaluation the Directors being evaluated shall be excluded from the meeting.

Evaluation of KMP and Senior Management Personnel

Criteria for evaluating performance of KMP (other than Directors) and Senior Management Personnel shall be as per the internal guidelines of the Company on performance management and development.

Criteria for performance evaluation of Other Employees

The respective Departmental Chiefs of the Company shall evaluate the performance of Other Employees. In this regard, the Chiefs shall decide upon the criteria for evaluating performance of Other Employees.

Remuneration of Directors and KMP :

The remuneration /compensation/commission etc. to Managing Director / Whole-time Director and remuneration of KMP will be determined by the Committee and recommended to the Board for approval. Commission to other Directors (including Independent Directors) shall be subject to the approval of the shareholders of the Company and Central Government, wherever required.

Remuneration/commission to Directors (including Independent Directors) as per the statutory provisions of the Act and the rules made thereunder for the time being in force within limits approved by shareholders shall be decided by the Board.

Increments to the existing remuneration/compensation structure payable to Managing Director / Wholetime Directors and KMP may be recommended by the Committee to the Board which should be within the slabs if any, approved by the shareholders in the case of Directors.

Sitting Fees

Non-Executive Directors including Independent Directors may receive remuneration by way of fees for attending meetings of Board or its committee within limits prescribed by the Central Govt.

Remuneration to Senior Management Personnel

The Committee has delegated its powers under this Policy with respect to Senior Management Personnel (other than their appointment) and other employees to Managing Directors and they shall be entitled to take decisions with respect to remuneration of Senior Management Personnel and other employees / their extension after attainment of applicable retirement age / employee welfare measure including provision of loans (with or without interest as per statutory provisions) through wage settlements or company rules/regulations or otherwise.

Remuneration to other employees

The respective Chiefs of the departments of the Company with Managing Director's approval, will determine from time to time the remuneration payable to Other Employees. The powers of the Committee in this regard have been delegated to the Administrative Chief of the Company.

Board Diversity

With a view to achieving a sustainable and balanced development, the Company sees increasing diversity at the Board level as an essential element in supporting the attainment of its strategic objectives and its sustainable development. The Company while appointing may consider the following criteria:

Appoint those persons who possess relevant experience, integrity, understanding, knowledge or other skill sets that may be considered by the Board as relevant in its absolute discretion, for the business of the Company etc.

The Board shall have the optimum combination of Directors, from different areas, fields, backgrounds and skill sets as may be deemed absolutely necessary.

The Board shall have members who have accounting or related financial management expertise and are financially literate.

Directors' Report
ANNEXURE –III TO THE DIRECTORS' REPORT
**PARTICULARS WITH RESPECT TO CONSERVATION OF ENERGY, ETC AS PER COMPANIES
(ACCOUNTS) RULES, 2014**
A. CONSERVATION OF ENERGY

	SARSUNA UNIT	DURGAPUR UNIT
i) The steps taken or impact on conservation of energy	Power factor had improved after a capacitor bank was installed in the Financial Year 2014-15. Consistent efforts are being employed to achieve optimum power factor.	
ii) The steps taken by the Company for utilizing alternate source of Energy	NIL	NIL
iii) The capital investment on energy conservation equipment	NIL	NIL

B. TECHNOLOGY ABSORPTION

i) The efforts made towards technology absorption	Several products, developed in-house, are being currently manufactured at out-sourced facilities. With the up-gradation of our own oral solid dosage manufacturing unit, these products, tablets as well as capsules, will be prepared in-house. These include digestive enzyme preparations, iron supplements, analgesics, etc.	
ii) The benefits derived like product improvement cost reduction, product development or import substitution	Developmental work on existing products towards quality improvement as well as cost reduction is a continuous process. Few such works, by the R & D department, has been implemented commercially.	
iii) In case of imported technology (imported during the last three year reckoned from the beginning of the financial year)	NIL	
a. The details of the technology imported.		
b. The year of import		
c. Whether the technology been fully absorbed		
d. If not fully absorbed, areas where absorption has not taken place, and the reasons thereof		
iv) The expenditure incurred on Research and Development	Capital = ₹ 1,79,550	
	Recurring = ₹ 1,29,29,508	
	Total = ₹ 1,31,09,058	
(Percentage of total turnover)	0.82%	

C. FOREIGN EXCHANGE EARNINGS AND OUTGO

i) The Foreign Exchange earned in terms of actual inflows during the year	₹ NIL
ii) The Foreign Exchange outgo during the year in terms of actual outflows	₹ 838.45 Lakhs (including ₹ 833.28 Lakhs for import of Raw Materials)

ANNEXURE - IV TO THE DIRECTORS' REPORT

EXTRACT OF ANNUAL RETURN AS ON THE FINANCIAL YEAR ENDED ON 31st. MARCH, 2017.

[Pursuant to section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

i. CIN	U24231WB1936PLC008598
ii. Registration Date	27th. April, 1936
iii. Name of the Company	East India Pharmaceutical Works Limited
iv. Category / Sub-Category of the Company	Public Company limited by shares
v. Address of the Registered office and contact details	6, Nandalal Bose Sarani, Kolkata 700071 Tel: +91 2287 3004 /07/09/3041/ 22830709 Tele Fax: 91-33-22873852/22874289 Email : eastindia@eastindiapharma.org
vi. Whether listed company	No
vii. Name, Address and Contact details of Registrar and Transfer Agent, if any	C B Management Services (P) Limited P-22, Bondel Road, Kolkata 700 019 Phone: (033) 4011 6700 / 2280 6692 Fax: 91-33-2287 0263 E-mail: rta@cbmsl.com Website: www.cbmsl.com

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products / services	NIC Code of the Product / service	% to total turnover of the Company
1	Manufacture of bulk drugs, Manufacture & sale of formulations & Trading Activities	304, 304.1	100%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

Sl. No.	Name And Address of The Company	CIN/GLN	Holding/ Subsidiary/ Associate	% of shares held	Applicable Section
1.	Qasar Healthcare Private Limited 102, S.P. Mukherjee Road, 3rd. Floor, Kolkata 700026	U85110WB1993PTC58605	Subsidiary	99.5%	Section 2(87)

Directors' Report

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i. Category-wise Share Holding

Category of Shareholders	No. of Shares held on 1st. April, 2016				No. of Shares held on 31st. March, 2017				% Change during the year	
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares		
A. Promoter										
1) Indian										
a) Individual/HUF	Nil	1828974	1828974	27.4023	Nil	1840004	1840004	27.5662	0.1639	
b) Central Govt.	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
c) State Govt(s)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
d) Bodies Corp.	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
e) Banks / FI	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
f) Any Other	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
Sub-total(A)(1):-	Nil	1828974	1828974	27.4023	Nil	1840004	1840004	27.5662	0.1639	
2) Foreign										
a) NRIs-Individuals	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
b) Other-Individuals	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
c) Bodies Corp.	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
d) Banks / FI	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
e) Any Other	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
Sub-total(A)(2):-	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
Total Shareholding of Promoter (A)=(A)(1)+(A)(2)	Nil	1828974	1828974	27.4023	Nil	1840004	1840004	27.5662	0.1639	
B. Public Shareholding										
1. Institutions										
a) Mutual Funds	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
b) Banks / FI	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
c) Central Govt	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	

Directors' Report

d) State Govt(s)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
e) Venture Capital Funds	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
f) Insurance Companies	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
g) FIs	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
h) Foreign Venture Capital Funds	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
i) Others (specify)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Sub-total(B)(1)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
2. Non Institutions									
a) Bodies Corp.									
(i) Indian	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
(ii) Overseas	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
b) Individuals									
(i) Individual shareholders holding nominal share capital upto Rs. 1 lakh	Nil	2940062	2940062	44.0491	Nil	2899026	2899026	43.4320	(0.6171)
(ii) Individual shareholders holding nominal share capital in excess of Rs. 1 lakh	Nil	1873308	1873308	28.0666	Nil	1901801	1901801	28.4920	0.4254
c) Others (Custodian of Enemy Property)	Nil	32174	32174	0.4820	Nil	34027	34027	0.5098	0.0278
Sub-total(B)(2)	Nil	4845544	4845544	72.5977	Nil	4834854	4834854	72.4338	(0.1639)
Total Public Shareholding (B)=(B)(1)+(B)(2)	Nil	4845544	4845544	72.5977	Nil	4834854	4834854	72.4338	(0.1639)
C. Shares held by Custodian for GDRs & ADRs									
Grand Total (A+B+C)	Nil	6674518	6674518	100.00	Nil	6674858	6674858	100.00	0.00

Directors' Report

ii. Shareholding of Promoters

Sl. No.	Shareholder's Name	Number of shares held on April 1, 2016			Number of shares held on March 31st, 2017			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1.	Amit Kumar Sen	643918	9.6474	Nil	645318	9.6683	Nil	0.02091
2.	Indrani Sen	337003	5.0491	Nil	343445	5.1456	Nil	0.0965
3.	Debarshi Duttgupta	650019	9.7388	Nil	651419	9.7597	Nil	0.0209
4.	Nabamita Duttgupta	198034	2.9670	Nil	199822	2.9938	Nil	0.0268
	Total	1828974	27.4023	Nil	1840004	27.5674	Nil	0.1651

iii. Change in Promoters' Shareholding for the Financial Year 2016-17

Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
	No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1. Amit Kumar Sen				
At the beginning of the year	643918	9.6474	643918	9.6474
19/08/2016 (Buy)	1287	0.0192	645205	9.6666
09/09/2016 (Buy)	113	0.0017	645318	9.6683
At the end of the year			645318	9.6683
2. Indrani Sen				
At the beginning of the year	337003	5.0491	337003	5.0491
18/03/2017 (Buy)	6442	0.0965	343445	5.1456
At the end of the year			343445	5.1456
3. Debarshi Duttgupta				
At the beginning of the year	650019	9.7388	650019	9.7388
09/09/2016 (Buy)	1400	0.0209	651419	9.7597
At the end of the year			651419	9.7597
4. Nabamita Duttgupta				
At the beginning of the year	198034	2.9670	198034	2.9670
19/08/2016 (Buy)	149	0.0022	198183	2.9692
31/03/2017 (Buy)	1639	0.0246	199822	2.9938
At the end of the year			199822	2.9938

iv. Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs)

Top Ten Shareholders	Date of Event	Buy/Sale	Shareholding as on April 1, 2016		Cumulative Shareholding during the year	
			No. of shares of the company	% of total shares	No. of shares of the company	% of total shares
1. Gita Sen						
At the beginning of the year	01/04/2016		112686	1.6883	112686	1.6883
Changes during the year	No change	—				
At the end of the year	31/03/2017		112686	1.6883	112686	1.68832

Directors' Report

2. Sanghamitra Duttagupta

At the beginning of the year	01/04/2016		109428	1.6395	109428	1.6395
Changes during the year	No change	—				
At the end of the year	31/03/2017		109428	1.6395	109428	1.6395

3. Atish Kumar Sen

At the beginning of the year	01/04/2016		109255	1.6369	109255	1.6369
Changes during the year	No change	—				
At the end of the year	31/03/2017		109255	1.6369	109255	1.6369

4. Mahendra Girdharilal

At the beginning of the year	01/04/2016		109255	1.6369	109255	1.6369
Change during the year	No change	—				
At the end of the year	31/03/2017		109255	1.6369	109255	1.6369

5. Diptish Kanti Basu

At the beginning of the year	01/04/2016		67758	1.0152	67758	1.0152
Changes during the year	27/07/2016	Sale	67758	1.0152	00	0.00
At the end of the year	31/03/2017		00	0.00	00	0.00

6. Aniruddha Basu

At the beginning of the year	01/04/2016		22640	0.3392	22640	0.3392
Change during the year	27/07/2016	Buy	67758	1.0152	90398	1.3543
At the end of the year	31/03/2017		90398	1.3543	90398	1.3543

7. Kalyan Sen

At the beginning of the year	01/04/2016		60750	0.9102	60750	0.9102
Change during the year	No change	—				
At the end of the year	31/03/2017		60750	0.9102	60750	0.9102

8. Ratnamala Ray

At the beginning of the year	01/04/2016		56740	0.8501	56740	0.8501
Change during the year	No change	—				
At the end of the year	31/03/2017		56740	0.8501	56740	0.8501

9. Tukaram Ganesh Kandalkar

At the beginning of the year	01/04/2016		42525	0.6371	42525	0.6371
Change during the year	24/05/2016	Sale	42525	0.6371	00	0.00
At the end of the year	31/03/2017			00	0.00	00 0.00

10. Rajan Tukaram Kandalkar

At the beginning of the year	01/04/2016		00	0.00	00	0.00
Change during the year	24/05/2016	Buy	42525	0.6371	42525	0.6371
At the end of the year	31/03/2017		42525	0.6371	42525	0.6371

11. Pranesh Raghunath Dhund

At the beginning of the year	01/04/2016		42525	0.6371	42525	0.6371
Change during the year	No change	—				
At the end of the year	31/03/2017		42525	0.6371	42525	0.6371

12. Indra Kumar Bagri

At the beginning of the year	01/04/2016		37402	0.5603	37402	0.5603
Change during the year	24/05/2016	Buy	1513	0.0227	38915	0.5830
At the end of the year	31/03/2017		38915	0.5830	38915	0.5830

Directors' Report

v. Shareholding of Directors and Key Managerial Personnel

For each of the Directors and KMP	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
	No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
At the Beginning of the year, April 1, 2016				
Subrata Ray	15126	0.2266	15126	0.2266
At the End of the year, March 31, 2017				
Subrata Ray	15126	0.2266	15126	0.2266

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness (in ₹)
Indebtedness at the beginning of the financial year				
i) Principal Amount	27,61,85,731	-	-	27,61,85,731
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	27,61,85,731	-	-	27,61,85,731
Change in Indebtedness during the financial year				
- Addition	5,37,60,389	-	-	5,37,60,389
- Reduction	-	-	-	-
Net Change	5,37,60,389	-	-	5,37,60,389
Indebtedness at the end of the financial year				
i) Principal Amount	32,99,46,120	-	-	32,99,46,120
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	32,99,46,120	-	-	32,99,46,120

Directors' Report

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager

Sl. No.	Particulars of Remuneration	Name of MD/WTD/ Manager		Total Amount (in ₹)
		Amit Kumar Sen	Debarshi Duttagupta	
1.	Gross salary			
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	42,00,000	31,75,000	73,75,000
	(b) Value of perquisites u/s 17(2) of the Income-tax Act, 1961	6,19,721	5,56,550	11,76,271
	(c) Profits in lieu of salary u/s 17(3) of the Income- tax Act, 1961	Nil	Nil	Nil
2.	Stock Option	Nil	Nil	Nil
3.	Sweat Equity	Nil	Nil	Nil
4.	Commission			
	- as % of profit	Nil	Nil	Nil
	- others, specify	Nil	Nil	Nil
5.	Others, please specify			
	Company's contribution to PF	5,04,000	3,81,000	8,85,000
6.	Company's contribution to Superannuation	—	4,95,000	4,95,000
7.	Total (A)	53,23,721	46,07,550	99,31,271
	Ceiling as per the Act		10% of the net profits of the Company	

B. Remuneration to other Directors:

Sl. No.	Particulars of Remuneration	Name of Directors			Total Amount (in ₹)			
		Probir Roy	Sukamal Chandra Basu	Dilip Samadar				
1.	Independent Directors							
	·Fee for attending board committee meetings	43,000	33,000	25,000	1,01,000			
	·Commission	—	—	—	—			
	·Others, please specify	—	—	—	—			
	Total (1)	43,000	33,000	25,000	1,01,000			
		Name of Directors			Total Amount (in ₹)			
2.	Other Non-Executive Directors	Ranabir Mukherji	Suman Kr. Mukerjee	Himadri Sengupta	Chiraranjan Addy	Abhijit Banerjee	Tapas Raychaudhury	
	Fee for attending board / committee meetings	30,000	43,000	20,000	40,000	40,000	20,000	2,86,000
	Commission	—	—	—	—	—	—	—
	Others, please specify	—	—	—	—	—	—	—
	Total (2)	30,000	43,000	20,000	40,000	40,000	20,000	2,86,000
	Total (B)=(1+2)							3,87,000
	Total Managerial Remuneration (A+B)							10,318,271
	Overall Ceiling as per the Act							11% of the net profits of the Company

Directors' Report

C. Remuneration to Key Managerial Personnel Other Than MD /Manager /WTD

Sl. No.	Particulars of Remuneration	Key Managerial Personnel			Total (in ₹)
		CEO	Company Secretary	CFO	
1.	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	—	12,35,300	11,14,100	23,49,400
	(b) Value of perquisites u/s 17(2) of the Income-tax Act, 1961	—	1,39,180	64,200	2,03,330
	(c) Profits in lieu of salary u/s 17(3) of the Income-tax Act, 1961	—	—	—	—
2.	Stock Option	—	Nil	Nil	Nil
3.	Sweat Equity	—	Nil	Nil	Nil
4.	Commission				
	- as % of profit	—	Nil	Nil	Nil
	- others, specify	—	Nil	Nil	Nil
5.	Others, please specify PF& Superannuation Contribution	—	2,26,800	2,38,140	4,64,940
6.	Total	—	16,01,280	14,16,440	30,17,720

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the companies Act	Brief description	Details of Penalty/ Punishment/ Compounding fees imposed	Authority[RD /NCLT/Court]	Appeal made. If any (give details)
A. Company Penalty Punishment Compounding]				
B. Directors Penalty Punishment Compounding			Not Applicable		
C. Other Officers In Default Penalty Punishment Compounding					

Independent Auditors' Report

To The Members of **EAST INDIA PHARMACEUTICAL WORKS LIMITED**

Report on the Standalone Financial Statements

We have audited the accompanying standalone financial statements of East India Pharmaceutical Works Limited ("the Company"), which comprise the Balance Sheet as at 31st March, 2017, the Statement of Profit and Loss, the Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities ; selection and application of appropriate accounting policies ; making judgments and estimates that are reasonable and prudent ; and design, implementation and maintenance of adequate internal financial controls, that are operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31st March, 2017 and its profit and its cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report that :
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

Auditors' Report

- c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of written representations received from the directors as on 31st March, 2017 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2017, from being appointed as a director in terms of Section 164(2) of the Act.
- f) We give in the Annexure a report on the internal financial control in the Company.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us :
 - (i) The Company does not have any pending litigations which would impact its financial position.
 - (ii) The Company did not have any long-term contract including derivative contracts for which there were any material foreseeable losses.
 - (iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - (iv) The Company has provided requisite disclosures in the financial statements as to holdings as well as dealings in Specified Bank Notes during the period from 8th November, 2016 to 30th December, 2016. Based on audit procedures and relying on the management representation we report that the disclosures are in accordance with books of account maintained by the Company and as produced to us by the Management.
2. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Government of India, Ministry of Corporate Affairs, in terms of sub-section (11) of Section 143 of the Act, we give in the Annexure a statement on the matters specified in paragraphs 3 and 4 of the Order.

Kolkata,
Dated, the 7th. August, 2017

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693

Annexure to the Independent Auditors' Report of even date on the Standalone Financial Statements of East India Pharmaceutical Works Limited

Statement under Companies (Auditor's Report) Order, 2016

1.
 - a) The Company is maintaining proper records showing full particulars including quantitative details and situation of its fixed assets.
 - b) The fixed assets are physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification.
 - c) The title deeds of immovable properties, other than self constructed buildings, are held in the name of the Company.
2. During the year, inventories were physically verified by the management at reasonable intervals. The discrepancies noticed on physical verification of inventories were not material and have been properly dealt with in the books of account.

Auditors' Report

3. According to the information and explanations given to us and as certified by the management, the Company has not granted any loan, secured or unsecured to companies, firms, limited liability partnerships or other parties covered in the register maintained under Section 189 of the Act.
4. According to the information and explanations given to us and as certified by the management, the Company has not granted any loans or made any investment or provided any guarantee or security as per provisions of Sections 185 and 186 of the Act.
5. The Company has not accepted any deposits within the meaning of Section 73 to 76 of the Act and the rules framed there under.
6. Pursuant to the rules made by the Central Government of India, the Company is required to maintain cost records as prescribed under Section 148 (1) of the Act in respect of its products. We are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. However, we have not made a detailed examination of such records with a view to determine whether they are accurate or complete.
7. a) According to the records of Company, undisputed statutory dues including provident fund, employees state insurance, income tax, sales tax, service tax, customs duty, excise duty and value added tax have generally been regularly deposited with the appropriate authorities.
b) According to the information and explanations given to us, following are the particulars of disputed dues on account of income tax, excise duty, service tax and sales tax matters which have not been deposited by the Company :-

Name of the Statute	Nature of Dues	Amount (₹)	Relevant Period	Forum where dispute is pending
Income Tax Act, Tax1961	Income Tax	43,17,790	2011-2012 and 2012-2013	Commissioner of Income Tax (Appeals) - XII, Kolkata
Central Excise Act, 1944	Cenvat	1,27,500	2007-2008	Commissioner of Central Excise (Appeal-1) Kolkata
Central Excise Act, 1944	Central Excise Duty	2,61,23,380	2000-2001 to 2004-2005	Calcutta High Court
	Penalty	2,61,23,380		
	Interest	84,45,582		
Central Excise Act, 1944	Interest	23,508	2008-2009 to 2012-2013	Commissioner, (Appeal - III A), Central Excise, Kolkata
	Penalty	54,539		
Central Excise Act, 1944	Cenvat	1,51,054	2012-2013 to 2014-2015	Commissioner of Central Excise, (Appeal - I), Kolkata
	Penalty	1,51,054		
Central Excise Act, 1944	Service Tax	76,503	2012-2013	
	Penalty	76,503		
	Interest	1,27,499		
Central Excise Act, 1944	Service Tax	1,88,468	2012-2013	
	Penalty	1,88,468		
	Interest	57,669		
Central Excise Act, 1944	Service Tax	4,80,863	2010-2015	Commissioner Central Excise, (Appeal -II), Kolkata
	Penalty	4,80,863		
	Interest	4,85,413		
Central Excise	Service Tax	11,197	2009-2010 to 2011-2012	Commissioner, (Appeal - III A), Central Excise, Kolkata
	Penalty	11,197		
Tamil Nadu General Sales Tax Act	Penalty	2,45,205	2005-2006 and 2006-2007	Appellate Deputy Commissioner (CT), Chennai

Auditors' Report

U.P. Trade Tax Act	Central Sales Tax	58,728	2005-2006	Additional Commissioner, Grade - II (Appeals)
U.P. Trade Tax Act	U.P. Trade Tax	1,00,964	2005-2006	
U.P. Trade Tax Act	U.P. Trade Tax	38,340	2006-2007	
U.P. Trade Tax Act	Central Sales Tax	70,272	2006-2007	

8. According to the records of the Company and the information and explanations given to us, the Company has not defaulted in repayment of dues to its bankers.
9. During the year the Company has not raised any money through public offer. The term loans received during the year were applied for the purposes for which those were obtained.
10. According to the information and explanations given to us and as certified by the management no fraud on or by the Company was reported during the year.
11. Managerial Remuneration has been paid / provided in accordance with the provisions of Section 197 read with Schedule V of the Act.
12. The Company is not a Nidhi Company.
13. According to the information and explanations given to us all transactions with the related parties are in compliance with Section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the financial statements etc., as required by the applicable accounting standards.
14. The Company has not made any preferential allotment or private placement of securities during the year.
15. The Company has not entered into any non-cash transaction with its directors or persons related to any of them.
16. The Company is not required to be registered under Section 45 - IA of the Reserve Bank of India Act, 1934.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693

Kolkata,
Dated, the 7th. August, 2017

Annexure to the Independent Auditors' Report of even date on the Standalone Financial Statements of East India Pharmaceutical Works Limited

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of East India Pharmaceutical Works Limited ("the Company") as of March 31, 2017 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Report

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2017, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693

Kolkata,
Dated, the 7th. August, 2017

Balance Sheet

AS AT 31ST MARCH, 2017

	Note No.	31st March, 2017 ₹	31st March, 2016 ₹
I. EQUITY AND LIABILITIES			
(1) Shareholders' Funds			
(a) Share Capital	2	6,67,45,179	6,67,45,179
(b) Reserves and Surplus	3	35,85,15,761	33,95,23,059
(2) Non-current Liabilities			
(a) Long-Term Borrowings	4	2,43,57,254	1,80,13,635
(b) Long-Term Provisions	8A	4,72,99,000	4,56,61,000
(3) Current Liabilities			
(a) Short-Term Borrowings	5	29,14,08,268	24,53,53,648
(b) Trade Payables	6	24,34,53,727	27,50,20,562
(c) Other Current Liabilities	7	23,09,67,575	20,61,27,212
(d) Short-Term Provisions	8B	89,71,793	2,15,09,434
TOTAL		127,17,18,557	121,79,53,729
II. ASSETS			
(1) Non-Current Assets			
(a) Fixed Assets			
(i) Tangible Assets	9	10,45,92,362	9,55,26,338
(ii) Intangible Assets	9	16,11,131	22,87,616
(iii) Capital work-in-progress		8,14,00,352	6,27,11,030
(b) Non-Current investments	10	99,500	99,500
(c) Deferred Tax Assets (Net)	11	3,29,32,254	3,14,98,725
(d) Long-Term Loans and Advances	12	95,38,964	1,80,06,774
(2) Current Assets			
(a) Inventories	13	22,99,67,181	21,77,03,120
(b) Trade Receivables	14	56,02,56,728	58,43,73,826
(c) Cash and Cash Equivalents	15	20,23,19,883	15,27,51,766
(d) Short-Term Loans and Advances	16	4,70,00,202	5,09,95,034
(e) Other Current Assets	17	20,00,000	20,00,000
TOTAL		127,17,18,557	121,79,53,729
Significant Accounting Policies	1		

The accompanying notes numbered 1 – 38 form an integral part of the financial statements.

This is the Balance Sheet referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 7th. August, 2017

Sd/- R. Mukherji, P. Roy, H. Sengupta,
C. Addy, S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Duttgupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray
Kolkata, Dated, the 7th. August, 2017

Statement of Profit and Loss

FOR THE YEAR ENDED 31ST MARCH, 2017

	Note No.	31st March, 2017		31st March, 2016	
		₹	₹	₹	₹
I. REVENUE FROM OPERATIONS					
Revenue from Sales	18	159,75,19,234		157,63,80,054	
Less : Excise Duty		(9,78,08,328)	149,97,10,906	(9,19,36,450)	148,44,43,604
Other Operating Revenues	18		18,13,363		28,43,892
II. OTHER INCOME	19		9,81,053		8,62,316
III. TOTAL REVENUE (I + II)			150,25,05,322		148,81,49,812
IV. EXPENSES :					
Cost of materials consumed	20		43,31,69,561		44,99,08,847
Purchases of Traded Goods			1,42,36,050		74,93,699
Changes in inventories of Finished goods, Work-in-Progress and Traded Goods	21		(1,31,11,925)		(16,83,725)
Employee Benefits Expenses	23		50,23,96,480		46,26,09,928
Finance Costs	24		4,85,39,902		4,99,21,240
Depreciation and Amortisation Expenses			1,47,32,057		1,43,58,909
Research and Development Expenses	25		1,29,29,508		1,24,50,650
Other Expenses	26		46,40,66,739		44,40,99,969
Total Expenses			147,69,58,372		143,91,59,517
V. PROFIT BEFORE TAX (III – IV)			2,55,46,950		4,89,90,295
VI. TAX EXPENSES :					
(1) Current tax		46,00,000		1,30,00,000	
(2) Deferred tax		(14,33,529)		(6,67,614)	
(3) Tax Adj. of earlier Years		33,87,777	65,54,248	4,56,178	1,27,88,564
VII. PROFIT FOR THE YEAR (V-VI)			1,89,92,702		3,62,01,731
VIII. EARNINGS PER EQUITY SHARE :	27				
(1) Basic			2.85		5.42
(2) Diluted			2.85		5.42

The accompanying notes numbered 1 – 38 form an integral part of the financial statements.

This is the Statement of Profit and Loss referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 7th. August, 2017

Sd/- R. Mukherji, P. Roy, H. Sengupta,
C. Addy, S. C. Basu, S. K. Mukerjee,
Directors
A. Banerjee, T. Raychaudhury
Managing Directors
A. K. Sen, D. Dutttagupta
Secretary & CCO
N. Mukhopadhyay
Chief Financial Officer
S. Ray
Kolkata, Dated, the 7th. August, 2017

Cash Flow Statement

FOR THE YEAR ENDED 31ST MARCH, 2017

	31st March, 2017 ₹	31st March, 2016 ₹
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax & extraordinary items	2,55,46,950	4,89,90,295
Adjustments For :		
Depreciation / Amortisation	1,47,32,057	1,43,58,909
(Profit)/ Loss on sale of Fixed Assets	(6,37,946)	(1,66,375)
Interest Received	(3,03,188)	(6,53,338)
Interest Paid	4,85,39,902	4,99,21,240
Operating Profit before working capital changes	8,78,77,775	11,24,50,731
(Increase)/Decrease in Inventories	(1,22,64,061)	(49,18,651)
(Increase)/Decrease in Trade & Other Receivables	3,65,79,740	(3,51,23,418)
Increase/ (Decrease) in Trade & Other Payables	(50,12,622)	3,29,02,986
Cash generated from operations	10,71,80,832	10,53,11,648
Direct Tax paid	(1,39,29,899)	(1,01,52,063)
Net Cash Flow from Operating Activities	9,32,50,933	9,51,59,585
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(4,21,25,172)	(6,69,22,390)
Sale of Fixed Assets	9,52,200	10,17,000
Net Cash Flow from Investing Activities	(4,11,72,972)	(6,59,05,390)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from/(Repayment of) borrowings(Net)	5,37,60,389	5,38,38,830
Payment of Dividend and Dividend Tax	(80,33,519)	(80,33,519)
Interest Paid	(4,85,39,902)	(4,99,21,240)
Interest Received	3,03,188	6,53,338
Net Cash Flow from Financing Activities	(25,09,844)	(34,62,591)
Net Cash Inflow (A+B+C)	4,95,68,117	2,57,91,604
Cash & Cash Equivalents- Opening	15,27,51,766	12,69,60,162
Cash & Cash Equivalents- Closing	20,23,19,883	15,27,51,766
	4,95,68,117	2,57,91,604

The accompanying notes numbered 1 – 38 form an integral part of the financial statements.

This is the Cash Flow Statement referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 7th. August, 2017

Sd/- R. Mukherji, P. Roy, H. Sengupta,
C. Addy, S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Duttgupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray
Kolkata, Dated, the 7th. August, 2017

Notes forming part of Balance Sheet as at 31st March, 2017 and Statement of Profit and Loss for the year ended on 31st March, 2017

Note No.

1 Significant Accounting Policies

- (i) **Basis of Accounting :**
The accounts have been prepared on the principles of historical costs and going concern basis.
- (ii) **Revenue Recognition :**
All revenues are generally recognised on accrual basis. Gross sales is stated inclusive of Excise Duty, Sales Tax and VAT.
- (iii) **Fixed Assets :**
Fixed assets, including those utilised in R&D activities, are capitalised at cost of acquisition which includes freight, duties and taxes, incidental expenses and borrowing cost.
- (iv) **Borrowing Costs :**
Borrowing costs are recognised as expense in the period in which they are incurred, except those directly attributable to the acquisition and construction of qualifying assets.
- (v) **Depreciation :**
Depreciation is provided on the Written Down Value based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013.
- (vi) **Research and Development Expenses :**
Revenue expenditure on Research and Development is charged to revenue in the year in which it is incurred. Expenses of capital nature are capitalised.
- (vii) **Inventories :**
Inventories are valued at lower of Cost and Net Realisable Value. Cost is determined as follows :
- | | |
|---------------------------------------|---|
| (a) Raw Materials | : Weighted average basis |
| (b) Work-in-Progress | : Weighted average basis |
| (c) Finished Goods | : Cost of input plus appropriate overhead |
| (d) Traded Goods | : Cost |
| (e) Packing materials and consumables | : Weighted average basis |
- (viii) **Employee Benefits :**
Liabilities in respect of retirement benefits to employees are provided for as follows :
- (I) **Defined Benefit Plans :**
- Leave encashment benefits are provided for on the basis of Actuarial Valuation.
 - Superannuation Fund and Gratuity Fund on the basis of premium paid to the Life Insurance Corporation of India.
- (II) **Defined Contribution Plans :**
Provident / Pension Fund and ESI on the basis of actual liability accrued and paid to Government authorities.
- (ix) **Foreign Currency Transaction :**
Transaction in foreign currencies are accounted for at exchange rates prevailing on the date of transaction. Gain / Loss arising on account of rise or fall in overseas currencies vis-a-vis reporting currency between the date of transaction and that of payment is charged to revenue.
- (x) **Taxes on Income :**
Current Tax is determined as per the provisions of the Income Tax Act, 1961. Deferred Tax liabilities/assets are recognised, subject to the consideration of prudence, on timing difference, being the difference between taxable income and accounting income.
- (xi) Final dividend for the year will be considered once it is approved by the shareholders in the AGM.

Notes forming part of Balance Sheet as at 31st March, 2017 and
Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017		31st March, 2016	
	₹	₹	₹	₹
2 SHARE CAPITAL				
(a) <u>Authorised</u> :				
1,00,00,000 Ordinary Shares		10,00,00,000		10,00,00,000
(b) <u>Issued</u> :				
66,75,543 Ordinary Shares		6,67,55,430		6,67,55,430
<u>Subscribed and paid up</u> :				
66,74,858 Ordinary Shares fully called up		6,67,48,580		6,67,48,580
Less : Calls Unpaid (525 number of Shares)		3,401		3,401
		6,67,45,179		6,67,45,179
(c) Par value per share		10.00		10.00
(d) <u>Quantitative Reconciliation</u> (In Nos.) :				
Opening Balance as on 01.04.2016		66,74,858		66,74,858
Add : Shares issued during the year		NIL		NIL
Closing Balance as on 31.03.2017		66,74,858		66,74,858
(e) Shares held by each shareholder holding more than 5 percent shares specifying the number of shares held :				
<u>Name of the shareholder</u>		No. of shares		No. of shares
n Shri Amit Kumar Sen		6,45,318		6,43,918
n Shri Debarshi Duttagupta		6,51,419		6,50,019
(f) Aggregate number of shares allotted as fully paid-up bonus shares during the period of five years immediately preceding the date as at which the Balance Sheet is prepared		NIL		22,24,778
(g) Calls unpaid		3,401		3,401
1 Calls unpaid by Directors and Officers		NIL		NIL
3 RESERVES AND SURPLUS				
(a) General Reserve:				
Opening Balance		33,15,13,059		30,33,44,847
Add : Profit after tax for the year		1,89,92,702		3,62,01,731
		35,05,05,761		33,95,46,578
Less : Provision for Dividend NIL (PY 10%)		NIL		66,74,518
Provision for Dividend Distribution Tax		NIL	35,05,05,761	13,59,001
				33,15,13,059
(b) Other Reserves:				
(i) Investment Fluctuation Reserve		10,000		10,000
(ii) Contingency Reserve		80,00,000		80,00,000
		35,85,15,761		33,95,23,059

Notes forming part of Balance Sheet as at 31st March, 2017 and
Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017 ₹	31st March, 2016 ₹
4 LONG – TERM BORROWINGS		
Secured		
n Term Loan from United Bank of India (Repayable in quarterly instalments and secured by hypothecation of specific assets procured under loan)	2,24,90,717	1,68,82,880
n Car Loan from HDFC Bank Ltd. (Repayable in equated monthly instalments and secured against hypothecation of 7nos Vehicles)	18,66,537	11,30,755
	<u>2,43,57,254</u>	<u>1,80,13,635</u>
5 SHORT – TERM BORROWINGS		
Secured		
n From banks -		
n Cash Credit :		
l From United Bank of India	29,14,08,268	24,53,53,648
Nature of Security :		
Secured by hypothecation of entire current assets of the Company with additional collaterals of charge over immovable properties.	<u>29,14,08,268</u>	<u>24,53,53,648</u>
6 TRADE PAYABLES		
Sundry Creditors	24,34,53,727	27,50,20,562
	<u>24,34,53,727</u>	<u>27,50,20,562</u>

Notes forming part of Balance Sheet as at 31st March, 2017 and
Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017 ₹	31st March, 2016 ₹
7 OTHER CURRENT LIABILITIES		
(a) Current maturities of Long-Term Borrowings :		
n From Banks -		
1 From United Bank of India (Repayable in quarterly instalments and secured by hypothecation of specific assets procured under loan)	1,20,00,000	1,20,00,000
1 From HDFC Bank Ltd. (Repayable in equated monthly instalment and secured against hypothecation of 7nos Vehicles)	21,80,598	8,18,448
(b) Interest accrued and due on borrowings	4,24,026	3,24,107
(c) Unclaimed dividends*	1,08,05,296	95,79,359
(d) Other payables (Includes Statutory Dues)	20,55,57,655	18,34,05,298
	<u>23,09,67,575</u>	<u>20,61,27,212</u>

* There are no amounts due to be credited to Investor Education and Protection Fund.

8 PROVISIONS

A. Long Term Provision -

Provision for Leave Encashment	<u>4,72,99,000</u>	<u>4,56,61,000</u>
--------------------------------	--------------------	--------------------

B. Short Term Provision -

(a) Provision for Leave Encashment	56,41,000	42,03,000
(b) Provision for Income Tax (Net of Advance Tax of ₹ 12,69,207 Previous Year ₹ 37,27,085)	33,30,793	92,72,915
(c) Provision for Proposed Dividend	NIL	66,74,518
(d) Provision for Tax on Proposed Dividend	NIL	13,59,001
	<u>89,71,793</u>	<u>2,15,09,434</u>

Notes forming part of Balance Sheet as at 31st March, 2017 and Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No. 9 FIXED ASSETS

Reconciliation of Gross and Net Carrying Amount of Each Class of Assets

SI No	Particulars	Cost as on	Additions	Deletions	Cost as on	Depreciation / Amortisation		Net Value as on March 31, 2017
		March 31, 2016	during the year	March 31, 2017	Upto March 31, 2016	For the year 2016-2017	Upto March 31, 2017	
		₹	₹	₹	₹	₹	₹	₹
A. TANGIBLE ASSETS								
(a)	Land	7,82,047	-	-	7,82,047	-	-	7,82,047
(b)	Buildings	8,83,40,694	1,00,800	-	8,84,41,494	4,91,06,774	22,46,881	3,70,87,839
(c)	Plant and Equipment*	29,09,90,246	1,56,44,976	10,00,000	30,56,35,222	24,56,56,636	72,56,822	5,36,23,065
(d)	Computer	68,58,523	5,23,877	-	73,82,400	61,96,794	3,96,157	7,89,449
(e)	Furniture and Fixture	2,36,10,711	26,08,851	-	2,62,19,562	2,00,86,725	8,65,996	52,66,841
(f)	Vehicles	1,56,64,049	44,24,260	21,50,669	1,79,37,640	1,15,19,904	24,47,637	59,05,213
(g)	Office Equipment	1,82,16,972	1,33,086	-	1,83,50,058	1,63,70,071	8,42,079	11,37,908
	Sub Total	44,44,63,242	2,34,35,850	31,50,669	46,47,48,423	34,89,36,904	1,40,55,572	10,45,92,362
B. INTANGIBLE ASSETS								
	Copyrights, patents and other intellectual property rights, services and operating rights	1,56,47,278	-	-	1,56,47,278	1,33,59,662	6,76,485	16,11,131
	Sub Total	1,56,47,278	-	-	1,56,47,278	1,33,59,662	6,76,485	16,11,131
	A+B Grand Total	46,01,10,520	2,34,35,850	31,50,669	48,03,95,701	36,22,96,566	1,47,32,057	10,62,03,493

* Includes additions to Research and Development assets as detailed below :

(i) Plant and Equipment : ₹ 1,62,750 (₹ NIL)

(ii) Computer : ₹ 16,800 (₹ NIL)

Notes forming part of Balance Sheet as at 31st March, 2017 and
Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No. 9 FIXED ASSETS (Contd.)

SI No	Particulars	Cost as on	Additions	Deletions	Cost as on	Depreciation / Amortisation			Net Value
		March 31, 2015 ₹	during the year ₹	₹	March 31, 2016 ₹	Upto March 31, 2015 ₹	For the year 2015-2016 ₹	Deletions 2015-2016 ₹	as on March 31, 2016 ₹
A. TANGIBLE ASSETS									
(a)	Land	7,82,047	-	-	7,82,047	-	-	-	7,82,047
(b)	Buildings	8,83,40,694	-	-	8,83,40,694	4,65,76,298	25,30,476	-	3,92,33,920
(c)	Plant and Equipment*	28,69,21,465	40,68,781	-	29,09,90,246	23,89,46,968	67,09,668	-	4,53,33,610
(d)	Computer	64,05,296	4,53,227	-	68,58,523	58,46,258	3,50,536	-	6,61,729
(e)	Furniture and Fixture	2,29,29,407	6,81,304	-	2,36,10,711	1,90,64,489	10,22,236	-	35,23,986
(f)	Vehicles	1,70,14,514	30,14,063	43,64,528	1,56,64,049	1,32,30,331	18,03,474	35,13,901	41,44,145
(g)	Office Equipment	1,78,00,856	4,16,116	-	1,82,16,972	1,53,90,468	9,79,603	-	18,46,901
	Sub Total	44,01,94,279	86,33,491	43,64,528	44,44,63,242	33,90,54,812	1,33,95,993	35,13,901	9,55,26,338
B. INTANGIBLE ASSETS									
	Copyrights, patents and other intellectual property rights, services and operating rights	1,56,47,278	-	-	1,56,47,278	1,23,96,746	9,62,916	-	22,87,616
	Sub Total	1,56,47,278	-	-	1,56,47,278	1,23,96,746	9,62,916	-	22,87,616
	A+B Grand Total	45,58,41,557	86,33,491	43,64,528	46,01,10,520	35,14,51,558	1,43,58,909	35,13,901	9,78,13,954

*Includes additions to Research and Development assets : ₹ NIL (₹ 3,24,613)

Notes forming part of Balance Sheet as at 31st March, 2017 and
Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017 ₹	31st March, 2016 ₹
10 NON-CURRENT INVESTMENTS		
Investment in Equity Instruments -		
n 9,950 Equity Shares of ₹ 10 each fully paid up – Qasar Healthcare Pvt. Ltd. (Subsidiary Company – unquoted)	99,500	99,500
	99,500	99,500
11 DEFERRED TAX ASSETS (NET)		
<u>Deferred Tax Liabilities :</u>		
Depreciation as per Income Tax Act, 1961	6,87,72,727	6,42,96,936
Depreciation adjusted against Reserves and Surplus	19,30,697	19,30,697
Privilege Leave paid during the year	1,05,15,538	88,18,100
Research & Development Assets	1,03,57,586	1,02,98,155
Total (A)	9,15,76,548	8,53,43,888
<u>Deferred Tax Assets :</u>		
Depreciation charged in Accounts	9,58,67,743	9,09,91,432
Provision for Doubtful Debts	5,31,248	4,56,964
Provision for Leave Encashment for the year	2,81,09,811	2,53,94,217
Total (B)	12,45,08,802	11,68,42,613
Deferred Tax Asset (Net) (B-A)	3,29,32,254	3,14,98,725
12 LONG – TERM LOANS AND ADVANCES (Unsecured, Considered Good)		
(a) Capital Advances	43,97,655	1,30,53,681
(b) Security Deposits	51,41,309	49,53,093
	95,38,964	1,80,06,774
13 INVENTORIES (At Lower of Cost and Net Realisable Value)		
(a) Raw materials	3,15,12,352	3,01,22,519
(b) Work-in-progress	6,48,993	79,12,387
(c) Finished Goods	15,88,65,808	14,38,80,469
(d) Traded Goods	76,24,927	22,34,947
(e) Packing materials and consumables	3,13,15,101	3,35,52,798
	22,99,67,181	21,77,03,120
The above includes goods in transit as under :		
(a) Raw materials	NIL	33,77,900
(b) Finished Goods	48,64,011	1,23,774
	48,64,011	35,01,674

Notes forming part of Balance Sheet as at 31st March, 2017 and
Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	₹	31st March, 2017 ₹	₹	31st March, 2016 ₹
14 TRADE RECEIVABLES				
(i) Debts outstanding for a period exceeding six months :				
Unsecured, considered good		2,21,13,663		4,66,08,239
Unsecured, considered doubtful	59,12,786		56,88,362	
Less : Provision	<u>59,12,786</u>	NIL	<u>56,88,362</u>	NIL
(ii) Other Debts :				
Unsecured, considered good		53,81,43,065		53,77,65,587
		<u>56,02,56,728</u>		<u>58,43,73,826</u>
15 CASH AND CASH EQUIVALENTS				
(a) Cash and Cash Equivalents :				
n Cash in Hand		6,04,283		6,27,497
n Balances with Banks - In Current Accounts		19,09,10,304		14,25,44,910
(b) Other Bank Balances :				
n In Unclaimed Dividend Accounts		1,08,05,296		95,79,359
		<u>20,23,19,883</u>		<u>15,27,51,766</u>
16 SHORT – TERM LOANS & ADVANCES (Unsecured, Considered Good)				
(a) Security Deposits		43,98,417		41,47,431
(b) Other advances		4,26,01,785		4,68,47,603
		<u>4,70,00,202</u>		<u>5,09,95,034</u>
17 OTHER CURRENT ASSETS Unsecured Considered Good				
Realisable from EPFO		20,00,000		20,00,00
		<u>20,00,000</u>		<u>20,00,00</u>
18 REVENUE FROM OPERATIONS				
(a) Revenue from Sales	159,75,19,234		157,63,80,054	
Less : Excise Duty	<u>(9,78,08,328)</u>	149,97,10,906	<u>(9,19,36,450)</u>	148,44,43,604
(b) Other operating revenues :				
n Claim	16,190		7,15,500	
n Refund of Excise Duty	37,780		NIL	
n Others	<u>17,59,393</u>	18,13,363	<u>21,28,392</u>	28,43,892
		<u>150,15,24,269</u>		<u>148,72,87,496</u>
Additional Information :				
Details of revenue from sale of Manufactured Goods :				
Liquid		70,74,01,630		71,16,60,076
Tablets		65,65,36,325		57,52,18,479
Capsules		16,66,58,307		10,87,53,911
Others		3,90,69,794		5,68,03,442
		<u>156,96,66,056</u>		<u>145,24,35,908</u>

Notes forming part of Balance Sheet as at 31st March, 2017 and
Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017		31st March, 2016	
	₹	₹	₹	₹
18 REVENUE FROM OPERATIONS (Contd.)				
Details of revenue from sale of Traded Goods :				
Liquid		59,43,962		6,10,482
Tablets		1,19,12,135		64,37,465
Others		99,97,081		86,34,010
		<u>2,78,53,178</u>		<u>1,56,81,957</u>
19 OTHER INCOME				
(a) Interest Income		3,03,188		6,53,338
(b) Profit/(Loss) on sale of assets		6,37,946		1,66,375
(c) Other income		39,919		42,603
		<u>9,81,053</u>		<u>8,62,316</u>
20 COST OF MATERIALS CONSUMED				
(a) <u>Raw materials :</u>				
Opening Stock	3,01,22,519		3,31,20,906	
Add : Purchases	26,94,43,628		29,21,55,104	
	<u>29,95,66,147</u>		<u>32,52,76,010</u>	
Less : Closing Stock	<u>3,15,12,352</u>	26,80,53,795	<u>3,01,22,519</u>	29,51,53,491
(b) <u>Packing materials and consumables :</u>				
Opening Stock	3,35,52,798		2,73,19,485	
Add : Purchases	16,28,78,069		16,09,88,669	
	<u>19,64,30,867</u>		<u>18,83,08,154</u>	
Less : Closing Stock	<u>3,13,15,101</u>	16,51,15,766	<u>3,35,52,798</u>	15,47,55,356
		<u>43,31,69,561</u>		<u>44,99,08,847</u>
Details of materials consumed :				
Iodine		7,85,99,047		11,43,24,349
Others		35,45,70,514		33,55,84,498
		<u>43,31,69,561</u>		<u>44,99,08,847</u>
21 CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS				
<u>Opening Stock :</u>				
Finished Goods	14,38,80,469		15,13,72,131	
Work-in-progress	79,12,387		1,18,166	
Traded Goods	<u>22,34,947</u>	15,40,27,803	<u>8,53,781</u>	15,23,44,078
Less : <u>Closing Stock</u>				
Finished Goods	15,88,65,808		14,38,80,469	
Work-in-progress	6,48,993		79,12,387	
Traded Goods	<u>76,24,927</u>	16,71,39,728	<u>22,34,947</u>	15,40,27,803
		<u>(1,31,11,925)</u>		<u>(16,83,725)</u>

Notes forming part of Balance Sheet as at 31st March, 2017 and
Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017 ₹	31st March, 2016 ₹
22 ADDITIONAL INFORMATION :		
(a) Details of Opening and Closing Stock of Finished Goods (Manufactured) :		
<u>Opening Stock :</u>		
Liquid	5,65,65,930	6,37,18,091
Tablets	5,22,95,646	5,37,74,114
Capsules	2,10,84,319	2,83,80,562
Others	1,39,34,574	54,99,364
	<u>14,38,80,469</u>	<u>15,13,72,131</u>
<u>Closing Stock :</u>		
Liquid	6,45,39,918	5,65,65,930
Tablets	6,09,60,479	5,22,95,646
Capsules	3,00,75,083	2,10,84,319
Others	32,90,328	1,39,34,574
	<u>15,88,65,808</u>	<u>14,38,80,469</u>
(b) Details of Opening and Closing Stock of Traded Goods :		
<u>Opening Stock :</u>		
Liquid	7,54,755	2,90,418
Tablets	13,65,718	75,219
Others	1,14,474	4,88,144
	<u>22,34,947</u>	<u>8,53,781</u>
<u>Closing Stock :</u>		
Liquid	18,82,171	7,54,755
Tablets	41,54,481	13,65,718
Others	15,88,275	1,14,474
	<u>76,24,927</u>	<u>22,34,947</u>
23 EMPLOYEE BENEFITS EXPENSES		
(a) Salaries & Wages	43,19,34,464	39,88,53,142
(b) Contribution to Provident and Other Funds	5,62,16,924	4,93,78,599
(c) Workmen and Staff Welfare Expenses	1,42,45,092	1,43,78,187
	<u>50,23,96,480</u>	<u>46,26,09,928</u>
24 FINANCE COSTS		
(a) Interest on Overdraft	4,01,28,542	3,89,14,679
(b) Interest on Term Loans	4,49,114	1,80,275
(c) Other Interest and Bank Charges [including exchange difference of ₹ 12,33,579 (PY ₹ 18,77,383)]	79,62,246	1,08,26,286
	<u>4,85,39,902</u>	<u>4,99,21,240</u>

Notes forming part of Balance Sheet as at 31st March, 2017 and
Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017		31st March, 2016	
	₹	₹	₹	₹
25 RESEARCH AND DEVELOPMENT EXPENSES				
(i) In-house Research :				
(a) Salaries & Wages	94,72,514		83,36,454	
(b) Contribution to Provident and Other Funds	8,37,871		7,27,879	
(c) Workmen and Staff Welfare	1,14,728		NIL	
(d) Consumable Stores	3,02,265		9,81,022	
(e) Travelling Expenses	2,66,267		91,077	
(f) Repairs & Renewals	7,84,527		5,85,092	
(g) Miscellaneous Expenses	11,51,336	1,29,29,508	6,00,526	1,13,22,050
(ii) Contribution to External Research Organisations		NIL		11,28,600
		1,29,29,508		1,24,50,650

Note :

The above does not include Depreciation and Amortisation of ₹ 6,00,155 (previous year ₹ 9,09,557) pertaining to Research and Development assets.

26 OTHER EXPENSES

(a) Freight and Handling	4,50,81,645		4,63,53,116	
(b) Insurance	31,65,015		48,21,353	
(c) Power and Fuel	3,86,72,538		3,78,42,239	
(d) Payment to Auditors	6,44,000		6,37,290	
(e) Publicity and Sales Promotion	39,90,415		47,54,601	
(f) Rates, Taxes and License fees	36,05,608		15,76,254	
(g) Excise duty	(17,874)		34,92,983	
(h) Rent	1,64,65,011		1,29,03,201	
(i) Bad Debt	2,14,918		2,02,802	
(j) Provision for Doubtful Debts	2,24,424		1,65,413	
(k) Conversion Charges	3,96,18,426		3,87,10,534	
(l) Commission to C & F Agents	3,25,95,564		2,91,06,628	
(m) Discount	3,07,31,401		3,22,84,972	
(n) Repairs - Machineries	70,85,865		44,02,640	
- Buildings	24,32,215		20,27,424	
- Others	35,40,127	1,30,58,207	21,80,862	86,10,926
(o) Sales Tax		10,49,54,700		10,12,54,662
(p) Travelling and Conveyance		9,18,19,098		8,69,12,103
(q) Miscellaneous Expenses		3,92,43,643		3,44,70,892
		46,40,66,739		44,40,99,969

27 EARNINGS PER SHARE

Earnings per share has been computed as under :

(a) Profit after taxation for the year	1,89,92,702	3,62,01,731
(b) Number of Ordinary Shares	66,74,858	66,74,858
(c) Earnings per share on profit after taxation (Face Value ₹ 10.00 per share)		
- Basic	2.85	5.42
- Diluted	2.85	5.42

Notes forming part of Balance Sheet as at 31st March, 2017 and
Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.		31st March, 2017	31st March, 2016
		₹	₹

28 CONTINGENT LIABILITIES AND COMMITMENTS (to the extent not provided for)

(i) Contingent Liabilities :

(a) Claims against the company not acknowledged as debt :

n in respect of Income Tax matters (disputed)	43,17,790	43,17,790
n in respect of Central Excise Duty (disputed)	6,11,21,950	6,18,08,843
n in respect of Service Tax (disputed)	22,62,690	22,394
n in respect of Sales Tax matters (disputed)	5,13,509	5,13,509

(b) Guarantees	7,20,724	5,77,000
----------------	----------	----------

(ii) Commitments :

Estimated amount of contracts remaining to be executed on capital account and not provided for (Net of Advance)	2,40,70,902	3,54,95,049
---	-------------	-------------

29 DETAILS OF PAYMENT TO AUDITORS

1 As Auditor	4,50,000	4,25,000
1 For Taxation Matters	1,25,000	1,00,000
1 For Certification & Other Services	69,000	1,12,290
	<u>6,44,000</u>	<u>6,37,290</u>

30 DISCLOSURES ON RELATED PARTIES

(a) Related Party :

(i) **Qasar Healthcare Private Limited - Subsidiary (Shareholding 99.5%)**

(ii) Key Managerial Personnel

<u>Name</u>	<u>Designation</u>
Shri Amit Kumar Sen	Managing Director
Shri Debarshi Duttagupta	Managing Director
Shri Nirjhar Mukhopadhyay	Secretary & Chief Compliance Officer
Shri Subrata Ray	Chief Financial Officer

(iii) Relative of Key Managerial Personnel

Ms Satarupa Mukherjee	Sr. Executive-Corporate Affairs
-----------------------	---------------------------------

(b) Transactions with Related Party during the period :

(i) Receivable from Qasar Healthcare Private Limited	₹ 91,25,893
(ii) Total Remuneration paid to Key Managerial Personnel	₹ 1,29,48,991
(iii) Total Remuneration paid to relative of Key Managerial Personnel	₹ 10,48,388

31 VALUE OF IMPORTS (CIF VALUE)

Raw materials	₹ 833.28 lakhs	₹ 1020.09 lakhs
---------------	-----------------------	-----------------

32 VALUE OF IMPORTED AND INDIGENOUS RAW MATERIALS, PACKING MATERIALS & CONSUMABLES CONSUMED DURING THE YEAR 2016-2017

	31. 03. 2017 Amount (₹ in lakhs)	31. 03. 2017 % to Total	31. 03. 2016 Amount (₹ in lakhs)	31. 03. 2016 % to Total
(a) Imported	864.22	19.95	1060.04	23.56
(b) Indigenous	3467.48	80.05	3439.05	76.44
	<u>4331.70</u>	<u>100</u>	<u>4499.09</u>	<u>100</u>

Notes forming part of Balance Sheet as at 31st March, 2017 and
Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017 ₹	31st March, 2016 ₹
33 EXPENDITURE IN FOREIGN CURRENCIES (ON PAYMENT BASIS) :		
On account of Travelling	5,00,700	NIL
On account of other matters	16,494	18,926
34 EARNINGS IN FOREIGN CURRENCIES		
From Export	NIL	7,14,229
35 THE FOLLOWING DISCLOSURES ARE MADE FOR THE AMOUNTS DUE TO THE MICRO, SMALL AND MEDIUM ENTERPRISES :		
(a) Principal amount payable to suppliers at the year end	88,42,479	54,98,398
(b) Amount of interest paid by the Company in terms of Section 16 of the MSMED, alongwith the amount of the payment made to the supplier beyond the appointed day during the accounting year	NIL	NIL
(c) Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED	NIL	NIL
(d) Amount of interest accrued and remaining unpaid at the end of the accounting year	13,75,475	12,12,141
36 COMPANY HAS ONLY ONE PRIMARY SEGMENT, i.e., PRODUCTION AND SALE OF PHARMACEUTICAL PRODUCTS. INFORMATION REGARDING SECONDARY SEGMENT, i.e., GEOGRAPHICAL AREA IS GIVEN BELOW :		
Sales – Domestic	159,75,19,234	157,56,65,825
Sales – Export	NIL	7,14,229

37 Disclosure on Specified Bank Notes (SBN) :

In accordance with MCA notification G.S.R. 308(E) dated 30th March, 2017 details of Specified Bank Notes (SBN) and Other Denomination Notes (ODN) held and transacted during the period 8th November, 2016 to 30th December, 2016 are given below:

Particulars	SBN	ODN	Total
Closing Cash in Hand as on 8th November, 2016	1,72,500	2,42,021	4,14,521
Add: Permitted receipts	0	32,42,745	32,42,745
Less: Permitted Payments	0	30,18,695	30,18,695
Less: Amount deposited in Banks	1,72,500	0	1,72,500
Closing Cash in Hand as on 30th December, 2016	0	4,66,071	4,66,071

38 Figures for the previous years have been rearranged and regrouped, wherever necessary.

Kolkata,
Dated, the 7th. August, 2017

Sd/- R. Mukherji, P. Roy, H. Sengupta,
C. Addy, S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Duttgupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray

Independent Auditors' Report

To The Members of **EAST INDIA PHARMACEUTICAL WORKS LIMITED**

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of **EAST INDIA PHARMACEUTICAL WORKS LIMITED** (hereinafter referred to as "the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group"), comprising of the Consolidated Balance Sheet as at 31st March, 2017, the Consolidated Statement of Profit and Loss, the Consolidated Cash Flow Statement for the year then ended, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

Management's Responsibility for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation of these consolidated financial statements in terms of the requirements of the Companies Act, 2013 (hereinafter referred to as "the Act") that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. While conducting the audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Holding Company's preparation of the consolidated financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on whether the Holding Company has an adequate internal financial controls system over financial reporting in place and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Holding Company's Board of Directors, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give

Auditors' Report

a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31st March, 2017 and their consolidated profit and their consolidated cash flows for the year ended on that date.

Other Matters

Financial statements of the subsidiary, which reflect asset of Rs. 0.37 lacs as at 31st March, 2017, loss of Rs. 0.22 lacs and net cash flow of Rs. 0.22 lacs for the year then ended, have been audited by us.

Report on Other Legal and Regulatory Requirements

As required by Section 143(3) of the Act, we report that :

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
- b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books .
- c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
- d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors of the Holding Company as on 31st March, 2017 taken on record by the Board of Directors of the Holding Company and our report of its subsidiary company, none of the directors of the Group companies is disqualified as on 31st March, 2017 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) We give in the Annexure a report on the internal financial control which is based on the auditors' report of the holding company and its subsidiary company.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i) The Group does not have any pending litigation which would impact the consolidated financial statements.
 - ii) The Group did not have any long term contract including derivative contracts for which there are any material foreseeable losses on long-term contracts including derivative contracts.
 - iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv) The Group has provided requisite disclosures in the financial statements as to holdings as well as dealings in Specified Bank Notes during the period from 8th November, 2016 to 30th December, 2016. Based on audit procedures and relying on the management representation we report that the disclosures are in accordance with books of account maintained by the Group and as produced to us by the Management.

Kolkata,
Dated, the 7th. August, 2017

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693

Auditors' Report

Annexure to the Independent Auditors' Report of even date on the Consolidated Financial Statements of East India Pharmaceutical Works Limited

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **East India Pharmaceutical Works Limited** ("the Holding Company") and its subsidiary (together referred to as "the Group") as of March 31, 2017 in conjunction with our audit of the consolidated financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding Company and its subsidiary are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by these entities, considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Holding Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Group's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Auditors' Report

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Group has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2017, based on the internal control over financial reporting criteria established by these entities considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.

Kolkata,
Dated, the 7th. August, 2017

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693

Consolidated Balance Sheet

AS AT 31ST MARCH, 2017

	Note No.	31st March, 2017 ₹	31st March, 2016 ₹
I. EQUITY AND LIABILITIES			
(1) Shareholders' Funds			
(a) Share Capital	2	6,67,45,179	6,67,45,179
(b) Reserves and Surplus	3	34,93,71,237	33,03,99,991
(2) Minority Interests			
		(45,453)	(45,344)
(3) Non-current Liabilities			
(a) Long-Term Borrowings	4	2,43,57,254	1,80,13,635
(b) Long-Term Provision	8A	4,72,99,000	4,56,61,000
(4) Current Liabilities			
(a) Short-Term Borrowings	5	29,14,08,268	24,53,53,648
(b) Trade Payables	6	24,34,53,727	27,50,20,562
(c) Other Current Liabilities	7	23,09,69,575	20,61,29,512
(d) Short-Term Provisions	8B	89,71,793	2,15,09,434
TOTAL		126,25,30,580	120,87,87,617
II. ASSETS			
(1) Non-Current Assets			
(a) Fixed Assets			
(i) Tangible Assets	9	10,45,92,362	9,55,26,338
(ii) Intangible Assets	9	16,11,131	22,87,616
(iii) Capital work-in-progress		8,14,00,352	6,27,11,030
(b) Deferred Tax Assets (net)	10	3,29,32,254	3,14,98,725
(c) Long-Term Loans and Advances	11	95,38,964	1,80,06,774
(2) Current Assets			
(a) Inventories	12	22,99,67,181	21,77,03,120
(b) Trade Receivables	13	55,11,30,835	57,52,47,933
(c) Cash and Cash Equivalents	14	20,23,51,531	15,28,05,279
(d) Short-Term Loans and Advances	15	4,70,05,970	5,10,00,802
(e) Other Current Assets	16	20,00,000	20,00,000
TOTAL		126,25,30,580	120,87,87,617

Significant Accounting Policies 1

The accompanying notes numbered 1 – 37 form an integral part of the financial statements.

This is the Consolidated Balance Sheet referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 7th. August, 2017

Sd/- R. Mukherji, P. Roy, H. Sengupta,
C. Auddy, S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Dutttagupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray
Kolkata, Dated, the 7th. August, 2017

Consolidated Statement of Profit and Loss

FOR THE YEAR ENDED 31ST MARCH, 2017

	Note No.	31st March,2017 ₹	31st March,2016 ₹
I. REVENUE FROM OPERATIONS			
Revenue from Sales	17	159,75,19,234	157,63,80,054
Less : Excise Duty		(9,78,08,328)	(9,19,36,450)
Other Operating Revenues	17	18,13,363	28,43,892
II. OTHER INCOME	18	9,81,053	8,62,316
III. TOTAL REVENUE (I + II)		150,25,05,322	148,81,49,812
IV. EXPENSES :			
Cost of Materials Consumed	19	43,31,69,561	44,99,08,847
Purchases of Traded Goods		1,42,36,050	74,93,699
Changes in inventories of Finished Goods, Work-in-Progress and Traded Goods	20	(1,31,11,925)	(16,83,725)
Employee Benefits Expenses	22	50,23,96,480	46,26,09,928
Finance Costs	23	4,85,40,217	4,99,21,557
Depreciation and Amortization Expenses		1,47,32,057	1,43,58,909
Research and Development Expenses	24	1,29,29,508	1,24,50,650
Other Expenses	25	46,40,87,989	44,41,36,293
Total Expenses		147,69,79,937	143,91,96,158
V. PROFIT BEFORE TAX (III – IV)		2,55,25,385	4,89,53,654
VI. TAX EXPENSE :			
(1) Current Tax		46,00,000	1,30,00,000
(2) Deferred Tax		(14,33,529)	(6,67,614)
(3) Tax Adj. of Earlier Years		33,87,777	4,56,178
VII. PROFIT FOR THE YEAR (V-VI)		1,89,71,137	3,61,65,090
VIII. EARNINGS PER EQUITY SHARE :	26		
(1) Basic		2.84	5.42
(2) Diluted		2.84	5.42

The accompanying notes numbered 1 – 37 form an integral part of the financial statements.

This is the Consolidated Statement of Profit and Loss referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 7th. August, 2017

Sd/- R. Mukherji, P. Roy, H. Sengupta,
C. Auddy, S. C. Basu, S. K. Mukerjee,
Directors
A. Banerjee, T. Raychaudhury
Managing Directors
A. K. Sen, D. Dutttagupta
Secretary & CCO
N. Mukhopadhyay
Chief Financial Officer
S. Ray
Kolkata, Dated, the 7th. August, 2017

Consolidated Cash Flow Statement

FOR THE YEAR ENDED 31ST MARCH, 2017

	31st March, 2017 ₹	31st March, 2016 ₹
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Tax & Extraordinary Items	2,55,25,385	4,89,53,654
Adjustments For :		
Depreciation / Amortisation	1,47,32,057	1,43,58,909
(Profit)/ Loss on sale of Fixed Assets	(6,37,946)	(1,66,375)
Interest Received	(3,03,188)	(6,53,338)
Interest Paid	4,85,40,217	4,99,21,240
Operating Profit before working capital changes	8,78,56,525	11,24,14,090
(Increase)/Decrease in Inventories	(1,22,64,061)	(49,18,651)
(Increase)/Decrease in Trade & Other Receivables	3,65,79,740	(3,51,21,149)
Increase/ (Decrease) in Trade & Other Payables	(50,12,922)	3,29,03,006
Cash generated from operations	10,71,59,282	10,52,77,296
Direct Tax paid	(1,39,29,899)	(1,01,52,063)
Net Cash Flow from Operating Activities	9,32,29,383	9,51,25,233
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(4,21,25,172)	(6,69,22,390)
Sale of Fixed Assets	9,52,200	10,17,000
Net Cash Flow from Investing Activities	(4,11,72,972)	(6,59,05,390)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from/(Repayment of) borrowings(Net)	5,37,60,389	5,38,38,830
Payment of Dividend and Dividend Tax	(80,33,519)	(80,33,519)
Interest Paid	(4,85,40,217)	(4,99,21,240)
Interest Received	3,03,188	6,53,338
Net Cash Flow from Financing Activities	(25,10,159)	(34,62,591)
Net Cash Inflow (A+B+C)	4,95,46,252	2,57,57,252
Cash & Cash Equivalents - Opening	15,28,05,279	12,70,48,027
Cash & Cash Equivalents - Closing	20,23,51,531	15,28,05,279
	4,95,46,252	2,57,57,252

The accompanying notes numbered 1 – 37 form an integral part of the financial statements.

This is the Consolidated Cash Flow Statement referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 7th. August, 2017

Sd/- R. Mukherji, P. Roy, H. Sengupta,
C. Auddy, S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Dutttagupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray
Kolkata, Dated, the 7th. August, 2017

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017

Note No.

1 Significant Accounting Policies

- (i) **Basis of preparation :**
The Consolidated Financial Statements have been prepared in accordance with the generally accepted accounting principles in India including the Accounting Standards notified under the relevant provisions of the Companies Act, 2013.
- (ii) **Principles of Consolidation :**
The Consolidated Financial Statements relate to East India Pharmaceutical Works Limited ('the company') and its subsidiary company, Qasar Health Care Private Limited. The Financial Statements of the Company and its subsidiary company are combined on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after fully eliminating intra-group balances and intra-group transactions in accordance with Accounting Standard (AS-21) - "Consolidated Financial Statements". Minority Interest's share, being negative have been adjusted with Consolidated Reserve and Surplus.
- (iii) **Revenue Recognition :**
All revenues are generally recognised on accrual basis. Gross sales is stated inclusive of Excise Duty, Sales Tax and VAT.
- (iv) **Fixed Assets :**
Fixed assets, including those utilised in R&D activities, are capitalised at cost of acquisition which includes freight, duties and taxes, incidental expenses and borrowing cost.
- (v) **Borrowing Costs :**
Borrowing costs are recognised as expense in the period in which they are incurred, except those directly attributable to the acquisition and construction of qualifying assets.
- (vi) **Depreciation :**
Depreciation is provided on the Written Down Value based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013.
- (vii) **Research and Development Expenses :**
Revenue expenditure on Research and Development is charged to revenue in the year in which it is incurred. Expenses of capital nature are capitalised.
- (viii) **Inventories :**
Inventories are valued at Lower of Costs and Net Realisable Value. Cost is determined as follows :
- | | |
|---------------------------------------|---|
| (a) Raw Materials | : Weighted average basis |
| (b) Work-in-Progress | : Weighted average basis |
| (c) Finished Goods | : Cost of input plus appropriate overhead |
| (d) Traded Goods | : Cost |
| (e) Packing materials and consumables | : Weighted average basis |
- (ix) **Employee Benefits :**
Liabilities in respect of retirement benefits to employees are provided for as follows :
- (I) **Defined Benefit Plans :**
- Leave encashment benefits are provided for on the basis of actuarial valuation.
 - Superannuation Fund and Gratuity Fund on the basis of premium paid to the Life Insurance Corporation of India.
- (II) **Defined Contribution Plans :**
Provident / Pension Fund and ESI on the basis of actual liability accrued and paid to Government Authorities.
- (x) **Foreign Currency Transaction :**
Transaction in foreign currencies are accounted for at exchange rates prevailing on the date of transaction. Gain / Loss arising on account of rise or fall in overseas currencies vis-a-vis reporting currency between the date of transaction and that of payment is charged to revenue.
- (xi) **Taxes on Income :**
Current Tax is determined as per the provisions of Income Tax Act, 1961. Deferred Tax liabilities/assets are recognised, subject to the consideration of prudence, on timing difference, being the difference between taxable income and accounting income.
- (xii) Final dividend for the year will be considered once it is approved by the shareholders in the AGM.

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and
Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017		31st March, 2016	
	₹	₹	₹	₹
2 SHARE CAPITAL				
(a) <u>Authorised</u> :				
1,00,00,000 Ordinary Shares		10,00,00,000		10,00,00,000
(b) <u>Issued</u> :				
66,75,543 Ordinary Shares		6,67,55,430		6,67,55,430
<u>Subscribed and paid up</u> :				
66,74,858 Ordinary Shares fully called up		6,67,48,580		6,67,48,580
Less : Calls Unpaid (525 number of Shares)		3,401		3,401
		6,67,45,179		6,67,45,179
(c) Par value per share		10.00		10.00
(d) <u>Quantitative Reconciliation (in Nos)</u> :				
Opening Balance as on 01.04.2016		66,74,858		66,74,858
Add : Shares issued during the year		NIL		NIL
Closing Balance as on 31.03.2017		66,74,858		66,74,858
(e) Shares held by each shareholder holding more than 5 percent shares specifying the number of shares held :				
<u>Name of the shareholder</u>		No. of shares		No. of shares
n Shri Amit Kumar Sen		6,45,318		6,43,918
n Shri Debarshi Duttagupta		6,51,419		6,50,019
(f) Aggregate number of shares allotted as fully paid-up bonus shares during the period of five years immediately preceding the date as at which the Balance Sheet is prepared		NIL		22,24,778
(g) Calls unpaid		3,401		3,401
1 Calls unpaid by Directors and Officers		NIL		NIL
3 RESERVES AND SURPLUS				
(a) <u>General Reserve:</u>				
Opening Balance	33,15,13,059		30,33,44,847	
Add : Profit after tax for the year	1,89,92,702	35,05,05,761	3,62,01,731	33,95,46,578
Less : Provision for Dividend				
NIL (PY 10%)	NIL		66,74,518	
Provision for Dividend Distribution Tax	NIL	NIL	13,59,001	(80,33,519)
		35,05,05,761		33,15,13,059
Less : Share of loss from Subsidiary		(91,44,524)		(91,23,068)
		34,13,61,237		32,23,89,991
(b) <u>Other Reserves:</u>				
(i) Investment Fluctuation Reserve		10,000		10,000
(ii) Contingency Reserve		80,00,000		80,00,000
		34,93,71,237		33,03,99,991

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and
Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017 ₹	31st March, 2016 ₹
4 LONG – TERM BORROWINGS		
Secured		
n Term Loan from United Bank of India (Repayable in Quarterly instalments and secured by hypothecation of specific assets procured under loan)	2,24,90,717	1,68,82,880
n Car Loan from HDFC Bank Ltd. (Repayable in equated monthly instalments and secured against hypothecation of 7 nos Vehicles)	18,66,537	11,30,755
	<u>2,43,57,254</u>	<u>1,80,13,635</u>
5 SHORT – TERM BORROWINGS		
Secured		
n From banks -		
n Cash Credit :		
1 From United Bank of India	29,14,08,268	24,53,53,648
Nature of Security :		
Secured by hypothecation of entire current Assets of the Company with additional collaterals of charge over immovable properties.		
	<u>29,14,08,268</u>	<u>24,53,53,648</u>
6 TRADE PAYABLES		
Sundry Creditors	24,34,53,727	27,50,20,562
	<u>24,34,53,727</u>	<u>27,50,20,562</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and
Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017 ₹	31st March, 2016 ₹
7 OTHER CURRENT LIABILITIES		
(a) Current maturities of Long-Term Borrowings :		
n From Banks -		
1 From United Bank of India (Repayable in Quarterly instalments and secured by hypothecation of specific assets procured under loan)	1,20,00,000	1,20,00,000
1 From HDFC Bank Ltd. (Repayable in equated monthly instalments and secured against hypothecation of 7 nos. Vehicles)	21,80,598	8,18,448
(b) Interest accrued and due on borrowings	4,24,026	3,24,107
(c) Unclaimed dividends *	1,08,05,296	95,79,359
(d) Other payables - (Includes Statutory Dues)	20,55,59,655	18,34,07,598
	<u>23,09,69,575</u>	<u>20,61,29,512</u>

* There are no amounts due to be credited to Investor Education and Protection Fund.

8 PROVISIONS

A. Long Term Provision -		
Provision for Leave Encashment	<u>4,72,99,000</u>	<u>4,56,61,000</u>
B. Short Term Provision -		
(a) Provision for Leave Encashment	56,41,000	42,03,000
(b) Provision for Income Tax (Net of Advance Tax of ₹ 12,69,207, Previous Year ₹ 37,27,085)	33,30,793	92,72,915
(c) Provision for Proposed Dividend	NIL	66,74,518
(d) Provision for Tax on Proposed Dividend	NIL	13,59,001
	<u>89,71,793</u>	<u>2,15,09,434</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No. 9 FIXED ASSETS

Reconciliation of Gross and Net Carrying Amount of Each Class of Assets

SI No	Particulars	Cost as on	Additions	Deletions	Cost as on	Depreciation / Amortisation		Net Value as on March 31, 2017 ₹
		March 31, 2016 ₹	during the year ₹	₹	March 31, 2017 ₹	For the year 2016-2017 ₹	Upto March 31, 2017 ₹	
A. TANGIBLE ASSETS								
(a)	Land	7,82,047	-	-	7,82,047	-	-	7,82,047
(b)	Buildings	8,83,40,694	1,00,800	-	8,84,41,494	22,46,881	5,13,53,655	3,70,87,839
(c)	Plant and Equipment*	29,09,90,246	1,56,44,976	10,00,000	30,56,35,222	72,56,822	25,20,12,157	5,36,23,065
(d)	Computer	68,58,523	5,23,877	-	73,82,400	3,96,157	65,92,951	7,89,449
(e)	Furniture and Fixture	2,36,10,711	26,08,851	-	2,62,19,562	8,65,996	2,09,52,721	52,66,841
(f)	Vehicles	1,56,64,049	44,24,260	21,50,669	1,79,37,640	24,47,637	1,20,32,427	59,05,213
(g)	Office Equipment	1,82,16,972	1,33,086	-	1,83,50,058	8,42,079	1,72,12,150	11,37,908
	Sub Total	44,44,63,242	2,34,35,850	31,50,669	46,47,48,423	1,40,55,572	28,36,415	10,45,92,362
B. INTANGIBLE ASSETS								
	Copyrights, patents and other intellectual property rights, services and operating rights	1,56,47,278	-	-	1,56,47,278	6,76,485	1,40,36,147	16,11,131
	Sub Total	1,56,47,278	-	-	1,56,47,278	6,76,485	1,40,36,147	16,11,131
	A+B Grand Total	46,01,10,520	2,34,35,850	31,50,669	48,03,95,701	28,36,41537,41,92,208	10,62,03,493	

* Includes additions to Research and Development assets as detailed below :

(i) Plant and Equipment : ₹ 1,62,750 (₹ NIL)

(ii) Computer : ₹ 16,800 (₹ NIL)

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No. 9 FIXED ASSETS (Contd.)

Sl No	Particulars	Cost as on March 31, 2015 ₹	Additions during the year ₹	Deletions ₹	Cost as on March 31, 2016 ₹	Depreciation / Amortisation			Net Value as on March 31, 2016 ₹
						Upto March 31, 2015 ₹	For the year 2015-2016 ₹	Deletions 2015-2016 ₹	
A. TANGIBLE ASSETS									
(a)	Land	7,82,047	-	-	7,82,047	-	-	-	7,82,047
(b)	Buildings	8,83,40,694	-	-	8,83,40,694	4,65,76,298	25,30,476	-	3,92,33,920
(c)	Plant and Equipment*	28,69,21,465	40,68,781	-	29,09,90,246	23,89,46,968	67,09,668	-	4,53,33,610
(d)	Computer	64,05,296	4,53,227	-	68,58,523	58,46,258	3,50,536	-	6,61,729
(e)	Furniture and Fixture	2,29,29,407	6,81,304	-	2,36,10,711	1,90,64,489	10,22,236	-	35,23,986
(f)	Vehicles	1,70,14,514	30,14,063	43,64,528	1,56,64,049	1,32,30,331	18,03,474	35,13,901	41,44,145
(g)	Office Equipment	1,78,00,856	4,16,116	-	1,82,16,972	1,53,90,468	9,79,603	-	18,46,901
	Sub Total	44,01,94,279	86,33,491	43,64,528	44,44,63,242	33,90,54,812	1,33,95,993	35,13,901	9,55,26,338
B. INTANGIBLE ASSETS									
	Copyrights, patents and other intellectual property rights, services and operating rights	1,56,47,278	-	-	1,56,47,278	1,23,96,746	9,62,916	-	22,87,616
	Sub Total	1,56,47,278	-	-	1,56,47,278	1,23,96,746	9,62,916	-	22,87,616
	A+B Grand Total	45,58,41,557	86,33,491	43,64,528	46,01,10,520	35,14,51,558	1,43,58,909	35,13,901	9,78,13,954

*Includes additions to Research and Development assets : ₹ NIL (₹ 3,24,613)

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and
Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017 ₹	31st March, 2016 ₹
10 DEFERRED TAX ASSETS (NET)		
Deferred Tax Liabilities :		
Depreciation as per Income Tax Act, 1961	6,87,72,727	6,42,96,936
Depreciation adjusted against Reserves and Surplus	19,30,697	19,30,697
Privilege Leave paid during the year	1,05,15,538	88,18,100
Research & Development Assets	1,03,57,586	1,02,98,155
Total (A)	<u>9,15,76,548</u>	<u>8,53,43,888</u>
Deferred Tax Assets :		
Depreciation charged in Accounts	9,58,67,743	9,09,91,432
Provision for Doubtful Debts	5,31,248	4,56,964
Provision for Leave Encashment for the year	2,81,09,811	2,53,94,217
Total (B)	<u>12,45,08,802</u>	<u>11,68,42,613</u>
Deferred Tax Asset (net) (B-A)	<u>3,29,32,254</u>	<u>3,14,98,725</u>
11 LONG – TERM LOANS AND ADVANCES (Unsecured, Considered Good)		
(a) Capital Advances	43,97,655	1,30,53,681
(b) Security Deposits	51,41,309	49,53,093
	<u>95,38,964</u>	<u>1,80,06,774</u>
12 INVENTORIES (At Lower of Cost and Net Realisable Value)		
(a) Raw materials	3,15,12,352	3,01,22,519
(b) Work-in-progress	6,48,993	79,12,387
(c) Finished Goods	15,88,65,808	14,38,80,469
(d) Traded Goods	76,24,927	22,34,947
(e) Packing materials and consumables	3,13,15,101	3,35,52,798
	<u>22,99,67,181</u>	<u>21,77,03,120</u>
The above includes goods in transit as under :		
(a) Raw materials	NIL	33,77,900
(b) Finished Goods	48,64,011	1,23,774
	<u>48,64,011</u>	<u>35,01,674</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017		31st March, 2016	
	₹	₹	₹	₹
13 TRADE RECEIVABLES				
(i) Debts outstanding for a period exceeding six months :				
Unsecured, considered good		2,21,13,663		3,74,82,346
Unsecured, considered doubtful	59,12,786		56,88,362	
Less : Provision	59,12,786	NIL	56,88,362	NIL
(ii) Other Debts :				
Unsecured, considered good		52,90,17,172		53,77,65,587
		<u>55,11,30,835</u>		<u>57,52,47,933</u>
14 CASH AND CASH EQUIVALENTS				
(a) Cash and Cash Equivalents :				
n Cash in Hand		6,04,283		6,27,497
n Balances with Banks - In Current Accounts		19,09,26,952		14,25,83,423
(b) Other Bank Balances :				
n In Unclaimed Dividend Accounts		1,08,05,296		95,79,359
n In Fixed Deposit Accounts		15,000		15,000
		<u>20,23,51,531</u>		<u>15,28,05,279</u>
15 SHORT – TERM LOANS & ADVANCES (Unsecured, Considered Good)				
(a) Security Deposits		43,98,417		41,47,431
(b) Other Advances		4,26,07,553		4,68,53,371
		<u>4,70,05,970</u>		<u>5,10,00,802</u>
16 OTHER CURRENT ASSETS				
Unsecured Considered Good				
Realisable from EPFO		20,00,000		20,00,000
		<u>20,00,000</u>		<u>20,00,000</u>
17 REVENUE FROM OPERATIONS				
(a) Revenue from Sales	159,75,19,234		157,63,80,054	
Less : Excise Duty	(9,78,08,328)	149,97,10,906	(9,19,36,450)	148,44,43,604
(b) Other Operating Revenues :				
n Claim	16,190		7,15,500	
n Refund of Excise Duty	37,780		NIL	
n Others	17,59,393	18,13,363	21,28,392	28,43,892
		<u>150,15,24,269</u>		<u>148,72,87,496</u>
Additional Information :				
Details of revenue from sale of Manufactured Goods :				
Liquid		70,74,01,630		73,71,69,650
Tablets		65,65,36,325		64,69,07,902
Capsules		16,66,58,307		13,45,12,367
Others		3,90,69,794		4,21,08,178
		<u>156,96,66,056</u>		<u>156,06,98,097</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and
Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017		31st March, 2016	
	₹	₹	₹	₹
17 REVENUE FROM OPERATIONS (Contd.)				
Details of revenue from sale of Traded Goods :				
Liquid		59,43,962		6,10,482
Tablets		1,19,12,135		64,37,465
Others		99,97,081		86,34,010
		<u>2,78,53,178</u>		<u>1,56,81,957</u>
18 OTHER INCOME				
(a) Interest Income		3,03,188		6,53,338
(b) Profit/(Loss) on sale of Assets		6,37,946		1,66,375
(c) Other income		39,919		42,603
		<u>9,81,053</u>		<u>8,62,316</u>
19 COST OF MATERIALS CONSUMED				
(a) Raw materials :				
Opening Stock	3,01,22,519		3,31,20,906	
Add : Purchases	26,94,43,628		29,21,55,104	
	<u>29,95,66,147</u>		<u>32,52,76,010</u>	
Less : Closing Stock	3,15,12,352	26,80,53,795	3,01,22,519	29,51,53,491
(b) Packing materials and consumables :				
Opening Stock	3,35,52,798		2,73,19,485	
Add : Purchases	16,28,78,069		16,09,88,669	
	<u>19,64,30,867</u>		<u>18,83,08,154</u>	
Less : Closing Stock	3,13,15,101	16,51,15,766	3,35,52,798	15,47,55,356
		<u>43,31,69,561</u>		<u>44,99,08,847</u>
Details of materials consumed :				
Iodine		7,85,99,047		11,43,24,349
Others		35,45,70,514		33,55,84,498
		<u>43,31,69,561</u>		<u>44,99,08,847</u>
20 CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS				
Opening Stock :				
Finished Goods	14,38,80,469		15,13,72,131	
Work-in-progress	79,12,387		1,18,166	
Traded Goods	22,34,947	15,40,27,803	8,53,781	15,23,44,078
Less : Closing Stock				
Finished Goods	15,88,65,808		14,38,80,469	
Work-in-progress	6,48,993		79,12,387	
Traded Goods	76,24,927	16,71,39,728	22,34,947	15,40,27,803
		<u>(1,31,11,925)</u>		<u>(16,83,725)</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and
Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017 ₹	31st March, 2016 ₹
21 Additional Information :		
(a) Details of Opening and Closing Stock of Finished Goods (Manufactured) :		
<u>Opening Stock :</u>		
Liquid	5,65,65,930	6,37,18,091
Tablets	5,22,95,646	5,37,74,114
Capsules	2,10,84,319	2,83,80,562
Others	1,39,34,574	54,99,364
	<u>14,38,80,469</u>	<u>15,13,72,131</u>
<u>Closing Stock :</u>		
Liquid	6,45,39,918	5,65,65,930
Tablets	6,09,60,479	5,22,95,646
Capsules	3,00,75,083	2,10,84,319
Others	32,90,328	1,39,34,574
	<u>15,88,65,808</u>	<u>14,38,80,469</u>
(b) Details of Opening and Closing Stock of Traded Goods :		
<u>Opening Stock :</u>		
Liquid	7,54,755	2,90,418
Tablets	13,65,718	75,219
Others	1,14,474	4,88,144
	<u>22,34,947</u>	<u>8,53,781</u>
<u>Closing Stock :</u>		
Liquid	18,82,171	7,54,755
Tablets	41,54,481	13,65,718
Others	15,88,275	1,14,474
	<u>76,24,927</u>	<u>22,34,947</u>
22 EMPLOYEE BENEFITS EXPENSES		
(a) Salaries & Wages	43,19,34,464	39,88,53,142
(b) Contribution to Provident and Other Funds	5,62,16,924	4,93,78,599
(c) Workmen and Staff Welfare Expenses	1,42,45,092	1,43,78,187
	<u>50,23,96,480</u>	<u>46,26,09,928</u>
23 FINANCE COSTS		
(a) Interest on Overdraft	4,01,28,542	3,89,14,679
(b) Interest on Term Loans	4,49,114	1,80,275
(d) Other Interest and Bank Charges (including exchange difference of ₹ 12,33,579 (PY ₹ 18,77,383))	79,62,561	1,08,26,603
	<u>4,85,40,217</u>	<u>4,99,21,557</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and
Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017		31st March, 2016	
	₹	₹	₹	₹
24 RESEARCH AND DEVELOPMENT EXPENSES				
(i) In-house Research :				
(a) Salaries & Wages	94,72,514		83,36,454	
(b) Contribution to Provident and Other Funds	8,37,871		7,27,879	
(c) Workmen & Staff Welfare	1,14,728		NIL	
(d) Consumable Stores	3,02,265		9,81,022	
(e) Travelling Expenses	2,66,267		91,077	
(f) Repairs & Renewals	7,84,527		5,85,092	
(g) Miscellaneous Expenses	11,51,336	1,29,29,508	6,00,526	1,13,22,050
(ii) Contribution to External Research Organisations		NIL		11,28,600
		<u>1,29,29,508</u>		<u>1,24,50,650</u>

Note :

The above does not include Depreciation and Amortisation of ₹ 6,00,155 (previous year ₹ 9,09,557) pertaining to Research and Development assets.

25 OTHER EXPENSES

(a) Freight and Handling	4,50,81,645		4,63,53,116	
(b) Insurance	31,65,015		48,21,353	
(c) Power and Fuel	3,86,72,538		3,78,42,239	
(d) Payment to Auditors	6,46,000		6,39,590	
(e) Publicity and Sales Promotion	39,90,415		47,54,601	
(f) Rates, Taxes and License fees	36,11,358		15,91,904	
(g) Excise duty	(17,874)		34,92,983	
(h) Rent	1,64,65,011		1,29,03,201	
(i) Bad Debt	2,14,918		2,05,071	
(j) Provision for Doubtful Debts	2,24,424		1,65,413	
(k) Conversion Charges	3,96,18,426		3,87,10,534	
(l) Commission to C & F Agents	3,25,95,564		2,91,06,628	
(m) Discount	3,07,31,401		3,22,84,972	
(n) Repairs - Machineries	70,85,865		44,02,640	
- Buildings	24,32,215		20,27,424	
- Others	35,40,127	1,30,58,207	21,80,862	86,10,926
(o) Sales Tax	10,49,54,700		10,12,54,662	
(p) Travelling and Conveyance	9,18,19,098		8,69,12,103	
(q) Miscellaneous Expenses	3,92,57,143		3,44,86,997	
	<u>46,40,87,989</u>		<u>44,41,36,293</u>	

26 EARNINGS PER SHARE

Earnings per share has been computed as under :

(a) Profit after taxation for the year	1,89,71,137	3,61,65,090
(b) Number of Ordinary Shares	66,74,858	66,74,858
(c) Earnings per share on profit after taxation (Face Value ₹ 10.00 per share)		
- Basic	2.84	5.42
- Diluted	2.84	5.42

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and
Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.		31st March, 2017 ₹	31st March, 2016 ₹
-----------------	--	------------------------------	-----------------------

27 CONTINGENT LIABILITIES AND COMMITMENTS
(to the extent not provided for)

(i) **Contingent Liabilities :**

(a) Claims against the company not acknowledged as debt :

n in respect of Income Tax matters (disputed)	43,17,790	43,17,790
n in respect of Central Excise Duty (disputed)	6,11,21,950	6,18,08,843
n in respect of Service Tax (disputed)	22,62,690	22,394
n in respect of Sales Tax matters (disputed)	5,13,509	5,13,509

(b) Guarantees	7,20,724	5,77,000
----------------	----------	----------

(ii) **Commitments :**

Estimated amount of contracts remaining to be executed on capital account and not provided for (Net of Advance)	2,40,70,902	3,54,95,049
---	-------------	-------------

28 DETAILS OF PAYMENT TO AUDITORS

1 As Auditor	4,52,000	4,27,300
1 For Taxation Matters	1,25,000	1,00,000
1 For Certification & Other Services	69,000	1,12,290
	6,46,000	6,39,590

29 DISCLOSURES ON RELATED PARTIES

(a) **Related Party :**

(i) Qasar Healthcare Privet Limited - Subsidiary (shareholding 99.5%)

(ii) **Key Managerial Personnel**

Name	Designation
Shri Amit Kumar Sen	Managing Director
Shri Debarshi Duttagupta	Managing Director
Shri Nirjhar Mukhorpadhyay	Secretary & Chief Compliance Officer
Shri Subrata Ray	Chief Financial Officer

(iii) **Relative of Key Managerial Personnel**

Ms Satarupa Mukherjee Sr. Executive-Corporate Affairs

(b) **Transactions with Related Party during the period :**

(i) Receivable from Qasar Healthcare Private Limited	₹ 91,25,893
(ii) Total Remuneration paid to Key Managerial Personnel	₹ 1,29,48,991
(iii) Total Remuneration paid to relative of Key Managerial Personnel	₹ 10,48,388

30 VALUE OF IMPORTS (CIF VALUE)

Raw materials	₹ 833.28 lakhs	₹ 1020.09 lakhs
---------------	----------------	-----------------

31 VALUE OF IMPORTED AND INDIGENOUS RAW MATERIALS, PACKING MATERIALS & CONSUMABLES CONSUMED DURING THE YEAR 2016-2017

	31. 03. 2017 Amount (₹ in lakhs)	31. 03. 2017 % to Total	31. 03. 2016 Amount (₹ in lakhs)	31. 03. 2016 % to Total
(a) Imported	864.22	19.95	1060.04	23.56
(b) Indigenous	3467.48	80.05	3439.05	76.44
	4331.70	100	4499.09	100

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Note No.	31st March, 2017 ₹	31st March, 2016 ₹
32 EXPENDITURE IN FOREIGN CURRENCIES (ON PAYMENT BASIS) :		
On account of Travelling	5,00,700	NIL
On account of other matters	16,494	18,926
33 EARNINGS IN FOREIGN CURRENCIES		
From Export	NIL	7,14,229
34 THE FOLLOWING DISCLOSURES ARE MADE FOR THE AMOUNTS DUE TO THE MICRO, SMALL AND MEDIUM ENTERPRISES :		
(a) Principal amount payable to suppliers at the year end	88,42,479	54,98,398
(b) Amount of interest paid by the Company in terms of Section 16 of the MSMED, alongwith the amount of the payment made to the supplier beyond the appointed day during the accounting year	NIL	NIL
(c) Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED	NIL	NIL
(d) Amount of interest accrued and remaining unpaid at the end of the accounting year	13,75,475	12,12,141
35 COMPANY HAS ONLY ONE PRIMARY SEGMENT, i.e., PRODUCTION AND SALE OF PHARMACEUTICAL PRODUCTS. INFORMATION REGARDING SECONDARY SEGMENT, i.e., GEOGRAPHICAL AREA IS GIVEN BELOW :		
Sales – Domestic	159,75,19,234	157,56,65,825
Sales – Export	NIL	7,14,229

36 Disclosure on Specified Bank Notes (SBN) :

In accordance with MCA notification G.S.R. 308(E) dated 30th March, 2017 details of Specified Bank Notes (SBN) and Other Denomination Notes (ODN) held and transacted during the period 8th November, 2016 to 30th December, 2016 are given below:

Particulars	SBN	ODN	Total
Closing Cash in Hand as on 8th November, 2016	1,72,500	2,42,021	4,14,521
Add: Permitted receipts	0	32,42,745	32,42,745
Less: Permitted Payments	0	30,18,695	30,18,695
Less: Amount deposited in Banks	1,72,500	0	1,72,500
Closing Cash in Hand as on 30th December, 2016	0	4,66,071	4,66,071

37 Figures for the previous years have been rearranged and regrouped, wherever necessary.

Kolkata,
Dated, the 7th. August, 2017

Sd/- R. Mukherji, P. Roy, H. Sengupta,
C. Auddy, S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Duttgupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray

Notes forming part of Consolidated Balance Sheet as at 31st March, 2017 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2017 (contd.)

Form AOC - 1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

**Statement containing salient features of the financial statement of subsidiaries/
Associate companies / joint ventures
Part "A": Subsidiaries**

Sl. No.	Name of the Company	Financial year of the Subsidiary Company ended on	Country of Incorporation	Percentage of Shareholding	Reporting currency and Exchange Rate
1	Qasar Healthcare Private Limited	31.03.2017	India	99.50%	INR

Name of the Subsidiary	Share Capital	Reserve & Surplus	Total Liabilities	Total Assets	Investment	Turn-over	Profit before taxes	Provision for taxation	Profit after taxes	Proposed Dividend
Qasar Healthcare Private Limited	100000	(9190,477)	9127893	37416	-	-	(21,565)	-	(21,565)	-

Part "B": Associates and Joint Ventures

The Company does not have any Associates or Joint Ventures, therefore statement pursuant to Section 129(3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures is not applicable.

For and on behalf of the Board of Directors

Place: Kolkata
Date: August 7, 2017

Sd/-Dr. Ranabir Mukherji
Chairman

East India Organisation

REGISTERED OFFICE

6, Nandalal Bose Sarani, Kolkata 700 071
Telephones : 2287 2262/3004/3007/3009/3041/2283 0709
Tele Fax : 91-33-22873852/22874289
E.mail : eastindia@eastindiapharma.org / cipwl@dataone.in
Website : www.eastindiapharma.org

FACTORIES

119, Biren Roy Road (West), Kolkata 700 061
Telephones : 2493 3135/3284/3384/3435/4283/6897
Tele Fax : 91-33-24937274
E.mail : eisf@eastindiapharma.org

Waria Road, Raturia
Durgapur 713 215
Telephones : 255 5813/6177
Tele Fax : 91-343-2555813
E.mail : eipwldgp@dte.vsnl.net.in

TRAINING CENTRE

102, Shyamaprosad Mukherjee Road
Kolkata 700 026
Telephone : 2455 2490



SALES OFFICES

	Telephones		Telephones
Assam		Maharashtra	
Nilamoni Phukan Path Christian Basti Guwahati - 781 005 Tele Fax : 91-361-2340745 E.mail : eipwl_guwahati@eastindiapharma.org	(0361)2340745 2340746 2340747	Mumbai 202-203, Syndicate Chambers 2nd Floor, Swami Nityananda Road Andheri (E), Mumbai - 400 069 Fax : 91-022-26848790 E.mail : eipwl_mumbai@eastindiapharma.org	(022)26848792
Bihar		Pune	
Jaintpur Kothi, Bank Road Patna - 800 001 Tele Fax : 91-612-2219178 E.mail : eipwl_patna@eastindiapharma.org	(0612)2219817	Yashwant Apartments Lane No. 4, Prabhat Road Deccan Gymkhana, Pune - 411 004 Fax : 91-20-25672377 E.mail : eipwl_pune@eastindiapharma.org	(020)25678687
Chhattisgarh		Orissa	
Ward No. 27, B.U.Complex, Janata Dal Mill Campus, Near FCI Godown Near Anant Vihar Colony, Raipur - 492 001 Tele Fax : E-mail : eipwl_raipur@eastindiapharma.org	(0771) 4020220	Plot No. 1108 Holding No. 417/C/1 Vikash Nagar, Badambari, Cuttack - 753 012 Fax : 91-671-2326782 E.mail : eipwl_cuttack@eastindiapharma.org	(0671)2322175 2316782
Delhi		Rajasthan	
3620/21 Netaji Subhas Marg Daryaganj, New Delhi - 110 002 Tele Fax : 91-11-23273985 E.mail : eipwl_delhi@eastindiapharma.org	(011)23262150 23283408 23277199	Bombay House Building Mirza Ismail Road Jaipur - 302 001 Tele Fax : 91-141-2373292 E.mail : eipwl_jaipur@eastindiapharma.org	(0141)2373292 2378341
Gujarat		Tamil Nadu	
Loksatta New Building Nagarwada Baroda - 390 001 Fax : 91-265-2432551 E.mail : eipwl_baroda@eastindiapharma.org	(0265)2432551 09327242551	Plot No. 8, 1st Floor 14th Cross Street Extn. Elumalai Nagar, New Colony, Chromepet, Chennai - 600 044 Tele Fax : 91-44-22380567 E.mail : eipwl_chennai@eastindiapharma.org	(044)22385312
Haryana		Talengana	
105, The Mall, Ambala Cantt. - 133 001 Fax : 91-171-4010402 E.mail : eipwl_ambala@eastindiapharma.org	(0171)2643280 2630277	Industrial Plots No. 148, 149 & 150 Quinol I.D.A., Mallapur, Hyderabad - 500 076 Tele Fax : 91-40-27178430 E.mail : eipwl_hyderabad@eastindiapharma.org	(040)27178915
Jharkhand		Uttar Pradesh	
3rd. Floor, Trikuta Hill, Kadru Road, Ranchi - 834 002 Ranchi - 834 001 Tele Fax : E-mail : eipwl_ranchi@eastindiapharma.org	(0651) 6900050	Lucknow No. 5, 4th Floor Saran Chamber-1, 5 Park Road Lucknow - 226 001 Tele Fax : 91-522-2235513 E.mail : eipwl_lucknow@eastindiapharma.org	(0522)2236251 2236371
Karnataka		Varanasi	
1 Mandi Veerappa Lane Off. Silver Jubilee Park Bangalore - 560 002 Tele Fax : 91-80-22235424 E.mail : eipwl_bangalore@eastindiapharma.org	(080)22222978 22235424 22130676	S-25/221-C1, First Floor, Rudra Vihar, Mahaveer Mandir Road, Tajpur, Orderly Bazar, Varanasi - 221 002 E.mail : eipwl_varanasi@eastindiapharma.org	(0522)2508625
Kerala		West Bengal	
Kenson Colony No. 9, 1st Floor, Door No. XLI/470 (Old No. 39/120) Krishnaswamy Road, Ernakulam, Cochin - 682 035 Fax : 91-484-2351467 E.mail : eipwl_ernakulam@eastindiapharma.org	(0484)2351467	Kolkata 136, Pathakpara Road Kolkata 700 060 Tele Fax : 91-33-24061926 E.mail : eipwl_kolkata@eastindiapharma.org	(033)24060369 24061916
Madhya Pradesh		Siliguri	
746/1 Napier Town Jabalpur - 482 001 Tele Fax : 91-761-4004622 E.mail : eipwl_jabalpur@eastindiapharma.org	(0761)2450040 4004622	Burdwan Road Siliguri - 734 005, Dt. Darjeeling Fax : 91-353-2502434 E.mail : eipwl_siliguri@eastindiapharma.org	(0353)2502629 2502434

Names & Addresses of C & F Agents as on 31st March, 2017

M/S A.C. SURGIPHARMA PVT. LTD.

K-59, Pratap Nagar
Delhi - 110 007
Phone No. : (011) 23693303, 23696719
Fax : 011-23697122
E-mail : us@acsurgipharma.com

M/S K. B. M. ENTERPRISES PVT. LTD.

Computer Zone Campus
Trimurti Place, Exhibition Road
Patna - 800 001
Phone No. : (0612) 2222448
E-mail : kbmenterprisespvtltd@yahoo.co.in

M/S MEHADIA & SONS

C/o Micropark Logistics Pvt. Ltd.
18th KM Stone, Opp. Deshonnati Press
Amravati Road, Gonkhedi
Nagpur - 440 023
Phone No. : (07118) 660355, 660356, 660340
Fax : 07118-660353
E-mail : eastindianagpur@gmail.com

M/S PAREKH INTEGRATED SERVICES PVT. LTD.

Circle - B - XXX, Plot No. 154, 1st Floor
Kailash Nagar, Focal Point Road, Sherpur
Ludhiana - 141 010 (Punjab)
Phone No. : (0161) 4621047, 5012220
E-mail : parekh.ludhiana@pispl.in

M/S M.K.S. ENTERPRISES

Balajee Complex
Near Argon Battery, Tapovan, Kokar
Ranchi - 834 001
Phone No. : (0651) 2545971
Mobile No. : 9308789320
Fax : 0651-2545971
E-mail : eastindiaranchi@gmail.com

M/S VA DISTRIBUTORS

Plot No. 2, 1st. Floor, Room No. 1
Subburaya Nagar, Thiruneermalai Main Road,
Chrompet, Chennai - 600 044
Phone No. : (044) 22730001, 22730058
E-mail : plachennai@gmail.com
vaeast02@gmail.com

M/S S. K. LOGISTICS

- 1) City Link Warehousing Complex
Building No. B-3, Mumbai Nashik Highway
S. No. 120-121, Village - Vadape, Bhiwandi
Thane - 421 302
Phone No. : (02522) 307575
Fax : 02522-307500
E-mail : sklogistics@sk1932.com
- 2) 7, Mangal Das Road
Mumbai - 400 002

M/S VISHWANATH REMEDIES

P.O. Industrial Estate, G. T. Road
Chandpur, Lahartara
Varanasi - 221 106 (U.P.)
Phone No. : (0542) 2371060, 3291117
Fax : (0542) 39167338
E-mail : eastindia.varanasi@gmail.com

M/S BARODA CHEMIST PVT. LTD.

Ground Floor, Gheekanta
Vad Falia, Raopura
Vadodara - 390 001
Phone No. : (0265) 2410395, 2432270
E-mail : barodachemist@yahoo.com

M/S INDIAN SALES

Ward No. 27, B.U.Complex
Daldal Seoni Road, Mowa,
Raipur - 492 001 (C.G.)
Phone No. : (0771) 4020220
E-mail : indiansalesryp@gmail.com

M/S RUCHI MEDICAL Pvt. Ltd.

18, P. D. Tandon Marg
Laxman Chowk
Dehradun - 248 001 (Uttaranchal)
Phone No. : (0135) 2722640, 3202400
Tele Fax : 0135-2624933
E-mail : ruchimed@yahoo.com

M/S M. M. ASSOCIATES

E - 207, Transport Nagar
Lucknow - 226 012, U.P.
Phone No. : (0522) 4010547, 4041626
Fax : 0522-4010546
E-mail : eipwllkocfa@gmail.com

M/S JAGOTA & SONS PVT. LTD.

Khasra No. 671-672
Opp. Saintli Petrol Pump (Bharat Petroleum)
N.H.-58, Meerut Road, Saintli
Ghaziabad - 201 206
Phone No. : (0120) 2675060
E-mail : eastindia@jagotagroup.com
jspl@jagotagroup.com

M/S J & J CORPORATION

9, Kenson Colony
Krishnaswamy Road, Ernakulam
Cochin - 682 035
Phone No. : (0484) 4031268
E-mail : eipwl_ernakulam@eastindiapharma.org

M/S SRI RAMAKRISHNA ENTERPRISES

Door No. 26-9-18/A, Rama Rao Street, Gandhinagar
Vijayawada - 520 003
Phone No. : (0866) 2422192
Mobile No. : 09440636373
E-mail : srkmtvja001@yahoo.com

